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Systems Biology of Platelet Activation
Abstract
Platelet intracellular calcium mobilization [Ca(t)]i is a measure of platelet activation and controls important
events downstream that contribute to hemostasis such as granule release, cyclooxygenase-1 and integrin
activation, and phosphatidylserine exposure. Accurate simulations of blood clotting events require prediction
of platelet [Ca(t)]i in response to combinatorial agonists. Therefore, a data-driven human platelet calcium
calculator was developed using neural network (NN) ensemble trained on pairwise agonist scanning (PAS)
data. PAS deployed all single and pairwise combinations of six important agonists (ADP, convulxin, thrombin,
U46619, iloprost and GSNO used at 0.1, 1, and 10xEC50 to stimulate platelet P2Y1/P2Y12, GPVI, PAR1/
PAR4, TP, IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited (250 nM apixaban), diluted
platelet rich plasma. PAS of 10 healthy donors (5 male, 5 female) provided [Ca(t)]i data for training 10 neural
networks (NN, 2-layer/12-nodes) per donor. Trinary stimulations were then conducted at all 0.1x and
1xEC50 doses (160 conditions) as was a sampling of 45 higher ordered combinations (four to six agonists).
The NN-ensemble average accurately predicted [Ca (t)]i beyond the single and binary training set for trinary
stimulations (R = 0.924). The 160 trinary synergy scores, a normalized metric of signaling crosstalk, were also
well predicted (R = 0.850) as were the calcium dynamics (R = 0.871) and high-dimensional synergy scores (R
= 0.695) for the 45 higher ordered conditions. The calculator even predicted sequential addition experiments
(n = 54 conditions, R = 0.921). NN-ensemble is a fast calcium calculator that proved to be useful for
multiscale clotting simulations that include spatiotemporal concentrations of ADP, collagen, thrombin,
thromboxane, prostacyclin, and nitric oxide.
From sequential addition experiments done in PAS, it was discovered that activating platelets with thrombin
in platelet-rich plasma (PRP) caused an attenuation of convulxin-induced, GPVI platelet receptor-mediated,
calcium mobilization when convulxin was added to PRP approximately six minutes later. This attenuation
effect was not observed when ADP and thromboxane analog, U46619 was used in place of thrombin. When
PAR-1 and PAR-4 receptor agonists (AYPGKF and SFLLRN) were used instead of thrombin for the initial
dispense, the subsequent convulxin-induced calcium response was also unaffected, demonstrating thrombin’s
unique role in causing attenuation of subsequent convulxin-induced calcium mobilization. Thrombin, unlike
ADP, U46619 or the PAR-1 and PAR-4 receptor agonists, is able to polymerize fibrinogen into fibrin. When
GPRP was added to prevent polymerization of fibrin, initial platelet activation by thrombin did not result in
attenuation of convulxin- induced calcium mobilization. This experiment was repeated using a mixture of
washed platelets and fibrinogen monomers instead of PRP and yielded similar results. The presence of
polymerized fibrin also reduced platelet deposition in a microfluidic assay on a collagen surface. These results
suggest that polymerized fibrin binds to and downregulates platelet GPVI, a platelet receptor that is important
to thrombus growth and is central to mediating hemostasis.
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ABSTRACT 
SYSTEMS BIOLOGY OF PLATELET ACTIVATION 
Mei Yan Lee 
Scott L. Diamond 
 
Platelet intracellular calcium mobilization [Ca(t)]i is a measure of platelet activation and 
controls important events downstream that contribute to hemostasis such as granule release, 
cyclooxygenase-1 and integrin activation, and phosphatidylserine (PS) exposure. Accurate 
simulations of blood clotting events require prediction of platelet [Ca(t)]i in response to 
combinatorial agonists. Therefore, a data-driven human platelet calcium calculator was developed 
using neural network (NN) ensemble trained on pairwise agonist scanning (PAS) data. PAS 
deployed all single and pairwise combinations of six important agonists (ADP, convulxin, 
thrombin, U46619, iloprost and GSNO used at 0.1, 1, and 10 x EC50 to stimulate platelet 
P2Y1/P2Y12, GPVI, PAR-1/PAR-4, TP, IP receptors, and guanylate cyclase, respectively, in 
Factor Xa-inhibited (250 nM apixaban), diluted platelet rich plasma (PRP). PAS of 10 healthy 
donors (5 male, 5 female) provided [Ca(t)]i data for training 10 neural networks (NN, 2-layer/12-
nodes) per donor. Trinary stimulations were then conducted at all 0.1 x and 1 x EC50 doses (160 
conditions) as was a sampling of 45 higher ordered combinations (four to six agonists).  The NN-
ensemble average accurately predicted [Ca(t)]i beyond the single and binary training set for 
trinary stimulations (R = 0.924).  The 160 trinary synergy scores, a normalized metric of 
signaling crosstalk, were also well predicted (R = 0.850) as were the calcium dynamics (R = 
0.871) and high-dimensional synergy scores (R = 0.695) for the 45 higher ordered conditions.  
The calculator even predicted sequential addition experiments (n = 54 conditions, R = 0.921).  
NN-ensemble is a fast calcium calculator that proved to be useful for multiscale clotting 
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simulations that include spatiotemporal concentrations of ADP, collagen, thrombin, thromboxane, 
prostacyclin, and nitric oxide. 
From sequential addition experiments done in PAS, it was discovered that activating 
platelets with thrombin in platelet-rich plasma (PRP) caused an attenuation of convulxin-induced, 
GPVI platelet receptor-mediated, calcium mobilization when convulxin was added to PRP eight 
minutes later. This attenuation effect was not observed when ADP and thromboxane analog, 
U46619 was used in place of thrombin. When PAR-1 and PAR-4 receptor agonists (AYPGKF 
and SFLLRN) were used instead of thrombin for the initial dispense, the subsequent convulxin-
induced calcium response was also unaffected, demonstrating thrombin’s unique role in causing 
attenuation of subsequent convulxin-induced calcium mobilization. Thrombin, unlike ADP, 
U46619 or the PAR-1 and PAR-4 receptor agonists, is able to polymerize fibrinogen into fibrin. 
When Gly-Pro-Arg-Pro (GPRP) was added to prevent polymerization of fibrin, initial platelet 
activation by thrombin did not result in attenuation of convulxin- induced calcium mobilization. 
This experiment was repeated using a mixture of washed platelets and fibrinogen instead of PRP 
and yielded similar results. The presence of polymerized fibrin also reduced platelet deposition in 
a microfluidic assay on a collagen surface. These results suggest that polymerized fibrin binds to 
and downregulates platelet GPVI, a platelet receptor that is important to thrombus growth and is 
central to mediating hemostasis.   
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 Introduction 
1.1 Platelet Activation 
Platelets are small anucleate blood cells that mediate thrombosis and hemostasis. In response 
to vessel wall injury, platelets are activated, forming a hemostatic plug to prevent further 
bleeding. Plate activation occurs in three overlapping phases: initiation, extension and 
perpetuation [1].  
In the initiation phase, platelets are initially captured, activated and adhere to the site of the 
vessel wall injury [2]. More specifically, at the vessel wall injury site, endothelium is disrupted, 
exposing collagen and von Willebrand factor (vWF). Platelets bind to vWF via platelet integrins 
GPIbα and αIIbβ3. Platelets then bind to collagen via platelet surface receptors (integrin α2β1 and 
glycoprotein (GP) VI). This forms a platelet monolayer on the collagen surface [2]. Binding of 
these platelet receptors to collagen also initiates intracellular signaling pathways that result in 
calcium mobilization, which is a measure of platelet activation. 
 In the extension phase, additional platelets are recruited to the growing thrombus. In this 
phase, activated platelets produce soluble agonists ADP (via granule release) and thromboxane 
(via arachidonic acid). Furthermore, platelets accelerate local thrombin generation via its 
membrane surface. These locally generated ADP and thromboxane binds to platelets and 
activates them via G protein coupled receptors (GPCRs) causing an increase in cytosolic calcium 
concentration and further release of ADP and thromboxane. Thrombin also activates platelets via 
binding of platelet PAR-1 and PAR-4 receptors, resulting in platelet calcium mobilization. 
Thrombin, ADP and thromboxane all activate platelets via G protein-coupled receptors (GPCRs) 
[2]. This positive feedback loop amplifies the initial signals and enables rapid activation and 
recruitment of platelets into a growing thrombus [1].  Specifically, platelet activation via GPCRs 
 2 
 
triggers intracellular signaling processes that convert platelet integrin αIIbβ3 into its active 
confirmation αIIbβ3a, resulting in fibrinogen/vWF-mediated platelet aggregation [2]. Platelets start 
to adhere to each other and accumulate on top of the initial platelet monolayer via fibrinogen-
αIIbβ3a and/or via fibrinogen-vWF bridges [3]. 
Events in the perpetuation phase take place to stabilize and to prevent premature 
disaggregation of the hemostatic platelet plug [2]. Ligand binding to platelet integrin αIIbβ3 
facilitates platelet adhesion and aggregation and triggers outside-in signaling [4]. Outside-in 
signaling ultimately results in platelet spreading, further granule secretion and stabilization of 
platelet adhesion and aggregation as well as clot retraction [4].  
Thrombin is also generated via Factor Xa via the tissue factor pathway [5]. In addition to 
activating platelets via its receptors PAR-1 and PAR-4, thrombin cleaves fibrinopeptide A from 
fibrinogen Aα-chains, thus initiating and catalyzing fibrin polymerization [6].  Fibrin cross-links 
and stabilizes the hemostatic plug, preventing premature disaggregation. The endothelium also 
synthesizes prostacyclin (increases adenyl cyclase activity) and nitric oxide (prevents degradation 
of cAMP by intracellular phosphodiesterases). Ultimately prostacyclin and nitric oxide increase 
intracellular cAMP levels and downregulates platelet signaling [7].  
1.2 Role of Thrombin 
Thrombin is a central enzyme involved in blood coagulation and platelet aggregation [8]. 
Thrombin is derived from prothrombin, a glycoprotein that is synthesized from the liver and 
released into the blood.  
During activation of the coagulation cascade, prothrombin is converted to thrombin with 
the help of prothrombinase, a complex that comprises serine protease FXa, cofactor Va, anionic 
phospholispholipids on platelet surface, as well as calcium ions [8]. Thrombin mediates 
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hemostasis through multiple functions. Most notably, thrombin catalyzes conversion of 
fibrinogen to fibrin, which helps stabilize hemostatic plugs in response to vessel wall injury. 
Thrombin also converts FXIII to FXIIIa, which adds structural integrity to fibrin network by 
covalent cross-linking of glutamine and lysine residues on fibrin molecules. Thrombin also 
activates platelets by binding to proteinase-activated receptors PAR-1 and PAR-4 found on 
platelets. Thrombin is an especially potent platelet agonist that mobilizes cytosolic calcium and 
results in granule release of soluble agonists, platelet aggregation, as well as surface expression of 
phosphatidylserine (PS, a procoagulant phospholipid) [9, 10].   
Because of thrombin’s multiple roles in mediating hemostasis, as well as its high potency 
as a platelet agonist in vivo, efficient regulation of thrombin activity is crucial to ensure proper 
clot formation. There are several serine protease inhibitors (serpin) that block the function of 
thrombin, most notably antithrombin. Antithrombin is present in blood at relatively high 
concentrations (2.3 µM) [8]. Many antiplatelet therapies have been developed to target thrombin 
function. For example, Factor Xa inhibitors such as rivaroxaban, apixaban and edoxaban have 
been developed to limit thrombin generation and coagulation, useful for stroke prevention and 
deep vein thrombosis (DVT) management.  PAR-1 and PAR-4 inhibitors have also been 
developed. For example, PAR-1 inhibitor vorapaxar has been approved as a treatment for patients 
with a history of myocardial infarction and peripheral artery disease [11].  
1.3 Role of Fibrin 
During coagulation, thrombin catalyzes the conversion of the soluble molecule, fibrinogen, 
to an insoluble molecule, fibrin. At the conclusion of hemostasis, fibrinolysis occurs to aid 
healing at the site of injury [12]. Plasmin is the enzyme that catalyzes fibrinolysis, it converts the 
stable insoluble fibrin clot into soluble products that can be cleared by the liver. Plasmin is 
derived from the activation of its zymogen, plasminogen (abudant in circulation, 2 µM) [12]. This 
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activation is catalyzed by tissue-type plasminogen activator (tPA, 70 pM in plasma) that is 
generated by endothelial cells [12]. Its function is regulated by plasminogen activator inhibitor 1 
(PA1-1). Plasmin hyperfunction results in bleeding at injury sites, whereas hypofunction has been 
associated with hypercoagulability and thrombosis. Many conditions such as trauma and DIC are 
marked by an increase in fibrin degradation products (FDP) such as D-dimers. Hyperfibrinolysis 
has been implicated in trauma-induced coagulopathy [13]. Several clinical assays have therefore 
been developed to quantify D-dimers [12].  
Trauma-induced platelet dysfunction is well observed but the underlying mechanisms are 
poorly understood [14]. Some studies show that in trauma patients, flow cytometric markers of 
platelet activation were elevated, despite impaired functional aperture closure times (both 
collagen/ADP and collagen/epinephrine closure times) [15]. Furthermore, platelet function falls 
within the first six hours of hospital admission but remains suppressed even up to 120 hours after 
injury [14]. These studies suggest that immediate platelet activation in response to the initial 
tissue injury may induce a prolonged refractory state, where a fraction of activated platelets have 
impaired function but remain in circulation [14]. Therefore, further studying the interaction 
between platelet and fibrin may shed light on potential mechanisms behind joint hyperfibrinolysis 
and platelet dysfunction as seen in patients following trauma.  
1.4 Role of GPVI 
GPVI is an immunoglobulin superfamily receptor that is expressed on platelet surface in 
association with the Fc receptor γ chain (FcRγ chain) [16]. There are approximately 3,700 copies 
of GPVI per platelet.   
GPVI plays an important role in thrombosis and hemostasis. It is well known that GPVI 
supports adhesion during the initiation phase of platelet activation via its interaction with 
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collagen. Collagen also activates platelets, resulting in elevated and sustained levels of cytosolic 
calcium that prompt important platelet procoagulant activity, such as procoagulant 
phosphatidylserine (PS) exposure, granule secretion and soluble platelet agonist secretion such as 
ADP and thromboxane that further activate platelets. In addition to these well-known GPVI 
functions, recently, GPVI has also been demonstrated to contribute significantly to thrombus 
growth and stabilization [16]. For example, in GPVI-deficient and GPVI-depleted mice with 
FeCl3 injury, the time to occlusion was prolonged, but not the initiation of thrombus formation  
[17]. In another study, GPVI has been shown to mediate thrombin generation in a collagen-
independent manner [18]. A common explanation in these findings is that fibrin is a ligand for 
GPVI, and the binding of fibrin to GPVI promotes thrombin generation.  
Because of the importance of GPVI in promoting thrombus growth and stabilization, GPVI 
has been highlighted recently as a desirable target for antithrombotic drug development. The 
inhibition or downregulation of GPVI was shown to impair thrombus formation but not disrupt 
hemostasis (does not increase bleeding), due to existing compensatory pathways.  
1.0 A human platelet calcium calculator trained by pairwise agonist 
scanning 
2.1 Abstract 
 
Since platelet intracellular calcium mobilization [Ca(t)]i controls granule release, 
cyclooxygenase-1 (COX-1) and integrin activation, and phosphatidylserine exposure, blood 
clotting simulations require prediction of platelet [Ca(t)]i in response to combinatorial agonists.  
Pairwise Agonist Scanning (PAS) deployed all single and pairwise combinations of six agonists 
(ADP, convulxin, thrombin, U46619, iloprost and GSNO used at 0.1, 1, and 10xEC50; 154 
 6 
 
conditions including a null condition) to stimulate platelet P2Y1/P2Y12, GPVI, PAR-1/PAR-4, TP, 
IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited (250 nM apixaban), 
diluted platelet rich plasma that had been loaded with the calcium dye Fluo-4 NW. PAS of 10 
healthy donors provided [Ca(t)]i data for training 10 neural networks (NN, 2-layer/12-nodes) per 
donor. Trinary stimulations were then conducted at all 0.1x and 1xEC50 doses (160 conditions) as 
was a sampling of 45 higher ordered combinations (four to six agonists).  The NN-ensemble 
average was a calcium calculator that accurately predicted [Ca (t)]i beyond the single and binary 
training set for trinary stimulations (R = 0.924).  The 160 trinary synergy scores, a normalized 
metric of signaling crosstalk, were also well predicted (R = 0.850) as were the calcium dynamics 
(R = 0.871) and high-dimensional synergy scores (R = 0.695) for the 45 higher ordered 
conditions.  The calculator even predicted sequential addition experiments (n = 54 conditions, R 
= 0.921).  NN-ensemble is a fast calcium calculator, ideal for multiscale clotting simulations that 
include spatiotemporal concentrations of ADP, collagen, thrombin, thromboxane, prostacyclin, 
and nitric oxide (NO).   
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2.2 Introduction 
 
Platelet activation during heart attack and stroke occurs through combined signaling 
pathways involving various receptors responding to collagen, thrombin, ADP, and thromboxane. 
Endothelial production of prostacyclin is highly protective against thrombotic platelet activation 
as revealed by the known cardiovascular risks of COX-2 inhibitors. Similarly, endothelial 
production of NO has many cardiovascular effects via vasodilation and platelet inhibition. The 
clinical importance of these pathways is seen in the number of drugs in clinical trials or approved 
that target GPVI signaling, thromboxane, ADP, or thrombin. More than 50 million U.S. adults 
take aspirin to inhibit platelet COX-1 production of thromboxane in order to reduce long-term 
risk of cardiovascular disease [19]. Clopidogrel antagonizes ADP activation of platelet P2Y12 
receptors and is widely prescribed. Numerous anticoagulants are approved to target the 
generation or activity of thrombin. 
Platelet activation occurs through multiple signaling pathways in which agonists bind 
specific receptors on the platelet to trigger signaling in a dose-dependent manner. During a 
clotting episode, platelets respond to exposed surface collagen, released ADP, synthesized 
thromboxane, and the serine protease thrombin, all while being simultaneously modulated by 
endothelial derived nitric oxide and prostacyclin. These receptor-mediated signaling pathways are 
not independent and significant crosstalk can occur (Figure 1-1). 
The Pairwise Agonist Scanning (PAS) method was first developed by Chatterjee et 
al.(2010) using EDTA-treated platelet rich plasma (PRP) to quantify and predict the interactions 
between multiple pathways (Figure 1-2) [20]. The PAS method measures platelet calcium 
responses to all individual and pairwise combinations of agonists at low, medium and high 
concentrations (154 conditions total for six agonists at 0.1, 1, and 10 x EC50, including a null 
condition). 
 8 
 
Because EDTA chelates extracellular calcium and prevents store operated calcium entry 
(SOCE), the measured calcium data obtained using EDTA-treated PRP is enriched in the 
regulatory events surrounding IP3-mediated calcium release from the dense tubular system 
(DTS). 
With PAS data, Chatterjee et al. were able to train an artificial neural network (NN) to 
predict platelet calcium response to combinations of agonists beyond the training data, such as 
trinary combinations, sequential additions of agonists, and combinatorial responses of four to six 
agonists [20].  
The NN model builds an estimate of higher order interactions (response to >2 agonists) 
by combination of the measured binary interactions. A metric called the pairwise synergy score 
was defined to quantify the extent of cross-talk between pairs of agonists (Figure 1-1B) [20]. The 
pairwise synergy score (Sij) was defined to be the difference between the integrated area (area 
under the curve) for the combined response to agonists i and j relative to the integrated area for 
both the individual agonist responses added together, normalized to the maximum absolute 
Sij[20]. In other words, the synergy score is a measure of deviation of the platelet response from 
the simple additive response of each agonist. A positive Sij value indicates synergistic behavior 
between agonists i and j whereas a negative Sij value indicates antagonistic or saturating behavior 
and Sij = 0 represents a purely additive response.  
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Figure 1-1 Platelet signaling pathway and neural network architecture. (A) The six agonists used in this study 
(ADP, convulxin, U46619, thrombin, iloprost, GSNO) and their respective platelet signaling pathways, all of which 
converge upon intracellular calcium mobilization. (B) A two-layer, 12-node neural network architecture was employed. 
Agonist concentrations at a given time point were fed into the processing layers; the layers then integrated the input 
signal with feedback at t = 1, 2, 4, 8, 16, 32, 64 and 128 seconds to calculate [Ca2+]i at the next time point. The pairwise 
synergy score (Sij) was also defined as the difference in integrated calcium response to two agonists used together and 
integrated response to agonists used individually, normalized by the maximum synergy score in the experiment. 
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Since many platelet pathways are triggered distally of IP3-released calcium and SOCE, 
the intracellular calcium concentrations can be used as a global metric of platelet activation. 
Calcium is the central “node” in platelet signaling, in that elevated calcium levels are central to 
downstream clotting events such as integrin activation, granule release, shape change, and 
phosphatidylserine exposure by platelets [21-23]. The ability to predict dynamic calcium traces 
for combinations of agonists enables the targeting of specific platelet pathways to increase or 
decrease platelet activity so as to achieve desired clinical outcome. NN trained on PAS data 
provides accurate calcium responses to different dose combinations of important agonists and is 
essential for simulating platelet function under flow. As an in silico predictor of calcium 
regulation, the NNs trained by PAS can be embedded in multi-scale simulations of platelet 
deposition under flow conditions. In the work of Flamm et al. (2011) [24], NN were trained via 
PAS using calcium-containing PRP and then used to predict platelet deposition rates on collagen 
in the absence of thrombin by accounting for platelet signaling in response to laboratory analogs 
of collagen, ADP, thromboxane, and prostacyclin. 
A universal platelet calcium calculator provides a reference for platelet function of a 
healthy human. Platelet gain of function or loss of function in patients can therefore be measured 
in a high dimensional approach using the PAS method. Furthermore, since the specific pathways 
in the platelet that contribute to platelet gain or loss of function can be identified by PAS as well, 
PAS can be used to predict the sensitivity and resistance of drugs that target those specific agonist 
pathways, even loss of function mutations have been discovered with PAS [24]. Additionally, the 
calcium calculator can be embedded into a multiscale simulation of clotting under defined 
hemodynamic conditions. 
In the current study, the PAS method was expanded for the use of exogenously added 
thrombin in the presence of normal calcium and included the potent platelet inhibitors iloprost 
and nitric oxide (NO). Thrombin is an extremely potent platelet activator via cleavage of platelet 
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PAR-1 and PAR-4 receptors. Additionally, to estimate average healthy human platelet responses, 
calcium data was obtained from 10 healthy donors as an ensemble-averaged predictor of platelet 
calcium. Distinct from the prior PAS in Chatterjee et al. (2010) where PAR-1 and PAR-4 agonist 
peptides were used with platelet rich plasma (PRP) treated with EDTA, the current study required 
a means to study exogeneously added thrombin without endogenous production of thrombin in 
PRP with normal calcium. In the current experimental design, blood was drawn into 250 nM 
apixaban (Ki = 0.08 nM) [25], a direct Factor Xa inhibitor, which does not alter extracellular 
calcium levels but prevents endogenous thrombin generation. This assay therefore allows the 
contribution of SOCE and includes the signaling distal of thrombin proteolytic activity on PAR-1 
and PAR-4. Furthermore, the NN-ensemble method was employed to increase accuracy and 
robustness in NN predictions. 
 
2.3 Materials and Methods 
 
2.3.1 Pairwise Agonist Scanning (PAS) 
Whole blood was drawn by venipuncture from healthy donors according to the University 
of Pennsylvania Institutional Review Board guidelines (protocol number: 805305), into a syringe 
containing apixaban (SelleckChem) with a final concentration of 250 nM. Donors self-reported to 
be free of any medications or alcohol use for three days prior to the blood draw. Female donors 
self-reported to not using oral contraceptives. Platelet rich plasma (PRP) was then obtained by 
subjecting the whole blood sample to centrifugation at 120g for 12 minutes. Then, 2 ml of PRP 
was incubated with a vial (single microplate size) of Fluo-4 NW dye mixture (Invitrogen) 
reconstituted with 7.8 ml of HEPES buffer and 200 μL of 77 mg/ml reconstituted probenecid 
(Invitrogen) for 30 minutes [20]. All single and pairwise combinations of six agonists (ADP, 
convulxin, thrombin, U46619, iloprost and GSNO) at low, medium and high concentrations (0.1, 
 12 
 
1, and 10X EC50), as well as a buffer condition (154 conditions total x 2 replicates) were 
dispensed into a 384-well plate (called the ‘agonist plate’) using a high throughput liquid handler 
(PerkinElmer Janus). The PAS agonists were: ADP (P2Y1/ P2Y12 activator, EC50 = 1 μM), 
convulxin (GPVI activator, EC50 = 2 nM), thrombin (PAR-1/PAR-4 activator, EC50 = 20 nM), 
U46619 (TP activator, EC50 = 1 μM), iloprost (IP activator, EC50 = 0.5 μM) and GSNO (NO 
donor, EC50 = 7 μM) (Figure A-1). ADP and GSNO were obtained from Sigma-Aldrich, 
convulxin from Pentapharm, thrombin from Haematologic Technologies Inc., U46619 and 
iloprost from Tocris Bioscience. After incubation with dye, the PRP was dispensed into a 384-
well plate (called the ‘read plate’). Both the agonist and read plate were loaded into a Molecular 
Devices FlexStation 3, a fluorescence reader with auto-pipetting capabilities. Agonists were 
dispensed to a column of wells containing the PRP, where well fluorescence F(t) was read and 
normalized by the pre-dispense baseline. Specifically, 20 μL of agonist was added to 30 μL of 
PRP in each well, giving a final volume of 50 μL. In each well, the final concentration of PRP 
after agonist addition was 12% PRP by vol., and the volume of calcium dye was 15 μL (30% dye 
by vol.). Readings were taken in intervals of 2.5 seconds. The fluorescence was read for 20 
seconds before dispense, and readings were taken for 210 seconds after each dispense (EX/EM, 
485 nm/525 nm). The entire plate was read, column-wise, in under 90 minutes. PAS was 
conducted on PRP from ten donors (50% male), each in replicate on two different days (20 PAS 
experiments total). In separate tests using indomethacin (Sigma-Aldrich) to block COX-1 and 
apyrase (Sigma-Aldrich) to degrade released ADP, there was no evidence for autocrine signaling 
in the dilute PRP conditions of the experiment (Figure A-2), as previously found with EDTA-
treated PRP [20].  
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Figure 1-2 Pairwise Agonist Scanning experimental method. 
 
2.3.2 Trinary, Higher Order Combinations and Sequential Addition Experiments 
In experiments with trinary mixtures of agonists, all single and trinary combinations of 
the same six agonists at two different concentrations (0.1x and 1x EC50), as well as a null buffer 
condition (173 conditions total x 2 replicates) were prepared in the agonist plate. This experiment 
was done once for each of the 10 PAS donors. There are 3,402 possible conditions involving four, 
five, or six agonists (higher order combinations of agonists) at low, medium and high 
concentrations. The higher order combination space was sampled in equal proportions 
(approximately 1.3% each of 4 to 6 agonist conditions). Thus, a total of n = 45 higher order 
combinations were sampled (16 four-agonist, 19 five-agonist, and 10 six-agonist conditions). 
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These experiments were done seven times spanning five donors (two repeat experiments for two 
of the donors), neither of which were present in the PAS training set. In the sequential addition 
experiments, all conditions involving sequential addition of three agonists (ADP, convulxin and 
U46619) at three different concentrations and a null buffer condition (55 conditions total x 2 
replicates) were prepared in the agonist plate. The sequential addition experiment was done once 
on a single donor. 
2.3.3 Calculation of Synergy Scores 
The pairwise synergy score (Sij) was defined to be the difference between the integrated 
calcium for the combined response to ij-agonists and the sum of the integrated calcium for both 
the individual agonist responses used independently, normalized by scaling to the maximum 
absolute synergy score observed in the experiment (Figure 1-1B) [20]. Synergy scores range from 
-1 to 1 (positive, synergistic; 0, additive; negative, antagonistic). Trinary synergy scores (Sijk) 
were also similarly calculated as the difference of the combined response to ijk-agonists from the 
response for all three individual agonist responses. In general, synergy scores (Sn) are defined by 
Eq. 1, where the variable Ai represents the integrated calcium for the response to agonist i used 
independently, and A1. . .n is the area under the curve for the response to agonists 1 through n used 
simultaneously (n = 6 maximum for the six agonists deployed). 
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2.3.4 Neural Network Training and Averaging 
The replicate wells in each PAS experiment duplicate were averaged before training. A 2-
layer, 12-node dynamic neural network (NN), as employed in Chatterjee et al. (2010), was trained 
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on each averaged PAS experiment 10 times (n = 100), each time with a different set of initial 
weights and randomized division of 154 single and pairwise time course data into training and 
validation sets (90%/10%) (Figure 1-1B). All neural network model construction and training 
were done using the MATLAB Neural Network Toolbox (MathWorks). Training on a NN was 
done for a maximum of 1000 epochs, where each epoch was one pass through the training set 
followed by testing of the validation set. The training set vectors were used to optimize the NN 
weights and the validation set was used to test the weights during training so as to ensure the NN 
did not over fit to the training set. Early stopping was also employed, in which training would 
stop if the validation set error did not improve after five epochs. At the end of the training of each 
NN, the optimized NN weights would typically match the predicted time series to the 
experimental time series with a mean squared error anywhere on the order of 10
–4
 to 10
–2
. 
Each of the 100 trained NNs was then given the trinary experiment agonist concentration 
inputs and the resulting calcium time trace predictions were averaged to give an overall prediction 
for the average trinary experiment platelet response. The resulting synergy scores were also 
calculated and compared to the actual synergy scores for the trinary experiments. Similarly, each 
of the 100 trained NNs were given the higher order combination and sequential addition 
experimental concentration inputs, and the resulting calcium time trace predictions were 
compared to the measured values. A summary of the experimental and computational workflow is 
shown in Figure 1-3. In the testing of NN predictive abilities, output from all 100 NNs were 
averaged to give a final prediction. This approach is an ensemble method [26]. Ensemble methods 
are commonly used to overcome the inherent instability problem with NNs [26]. NNs (along with 
decision trees, multivariate adaptive regression splines etc.) are inherently unstable in that small 
differences in training data or conditions (e.g. initial weights) may cause variations in final 
predictions. Generating an ensemble of NNs and combining their outputs to produce a single 
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prediction has been proven by Cunningham et al. (2000) to be a robust solution to this problem 
[26]. 
 
Figure 1-3 Experimental and computational workflow. The dataset consists of PAS experiments done in duplicate 
on PRP donated by ten donors (five male, five female). The duplicate experiments were averaged before training, i.e. n 
= 10. Each PAS experiment comprised a set of 154 calcium time traces, responses to all combinations of six agonists at 
three different concentrations and a buffer condition. A neural network was trained on each of the average PAS 
experiments giving a total of n = 100 trained neural networks. A different set of assay conditions (in this case, trinary 
combinations of the same six agonists at low and medium concentrations) are then input to each of the 100 trained 
neural networks (collectively called the ensemble NN) to generate predictions, which are then averaged and compared 
to the experimental average calcium time traces. These trinary combination experiments were done once each on the 
same ten donors, i.e. n = 10. 
 
In the testing of the NN on higher order combination experiments, two additional donors 
(one male, one female) were used in the training set (12 donors for a total of 120 NNs). None of 
the 12 donors used in the training set were present in the testing donor set (five donors for a total 
of seven experiments). The success of the higher order combination predictions suggests that the 
ensemble NN was sufficiently robust to predict outcomes of donor aggregates without their 
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donor-specific PAS data during training, and that the NN ensemble has learned calcium 
mobilization patterns of an average healthy human. Furthermore, the sequential addition 
experiment predictions points to the ability of the ensemble NN to predict the outcome of an 
individual donor, not just aggregate outcomes of donors, and without having PAS data of that 
specific testing donor during training. 
2.4 Results 
2.4.1 Neural network prediction of platelet responses to binary agonist stimulation 
The 10 x 10 NN-ensemble was trained on the pairwise agonist scanning (PAS) 
experiments of 10 donors and predicted the measured average pairwise calcium traces of those 
donors (Figure 1-4A-C) with a correlation coefficient of R = 0.975 (Figure 1-4C). Figure 1-4A 
indicates all 154 single and pairwise conditions used in the PAS with the corresponding calcium 
time traces (Figure 1-4B) and NN-predicted calcium time traces (Figure 1-4C). From Figure 
1-4A-C, the calcium response to convulxin rose slowly, but became highly elevated and was 
sustained. In contrast, calcium responses to ADP or U46619 displayed rapid onset but were 
weaker and more transient than calcium responses to convulxin and thrombin. Interestingly, the 
thrombin response displayed rapid calcium mobilization, prominent elevation, and was more 
sustained than calcium responses observed in earlier studies with PAR-1 and PAR-4 agonist 
peptides [20]. A total of 135 binary synergy scores (all pairs of six agonists at three 
concentrations) for the PAS experiment and the NN-prediction are shown in vector form (Figure 
1-4), representing the average human platelet phenotype. Both experimental and NN-predicted 
synergy values were plotted in heat map form in Figure 1-4D. Similar to the time series 
prediction, the NN ensemble was able to predict the measured average pairwise synergy scores of 
those ten donors (R = 0.937) (Figure 1-4E). Many synergy values clustered around the center of 
the range (Sij~0, additive) with slightly more negative values extending to full antagonism (Sij~ -
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1). The maximum synergy score did not exceed 0.5. The most negative synergies were found with 
pairwise mixtures that included iloprost. The experimental and NN-predicted synergy scores were 
also arranged by dose and agonist pairs (Figure 1-4F). From Figure 1-4F, iloprost was inhibiting 
for all agonists used in combination with it. GSNO was also inhibiting for most conditions, 
however, low dose GSNO slightly potentiated thrombin-induced calcium response. The 
combination of medium or high dose thrombin with medium dose convulxin was particularly 
synergistic, consistent with several findings [27, 28]. Also, thrombin signaling was synergistic 
with thromboxane signaling which is a novel observation since both agonists signal through Gq. 
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Figure 1-4 Neural network fit of PAS experiments. (A) PAS experiment input conditions: all single and pairwise 
combinations of six agonists at low, medium and high concentrations. (B) Measured average calcium time courses of 
ten donors in the PAS experiments. (C) The neural network trained on the PAS experiments of ten donors was able to 
fit the measured average pairwise calcium traces of those ten donors with a correlation coefficient of R = 0.975. (D) 
The experimental and NN-predicted 135 pairwise synergy scores for the PAS experiment. (E) The neural networks 
were able to fit the measured average pairwise synergy scores of those ten donors with a correlation coefficient of R = 
0.937. (F) The experimental and NN-predicted synergy scores arranged by dose and agonist pairs. 
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2.4.2 Neural network prediction of platelet responses to trinary agonist stimulation 
To test the predictive capability of the NN-ensemble beyond the training set, the NN-
ensemble was used to predict the calcium output of trinary agonist stimulations. To avoid 
saturation effects of agonist induced signaling, the trinary combination experiments comprised all 
trinary combinations of six agonists at only the low and medium doses (Figure 1-5). The NN 
ensemble trained only on the PAS experiments of ten donors in duplicate was able to predict the 
measured average trinary calcium traces of those donors with high accuracy (R = 0.924) (Figure 
1-5B-C). This demonstrated the de novo predictive capability of the neural network model. There 
were 160 trinary synergy scores for the trinary experiment consisting of all trinary combinations 
of six agonists at two different concentrations (0.1 and 1 x EC50). The NN trained only on the 
PAS experiments of ten donors in duplicate was able to predict the measured average trinary 
synergy scores of those ten donors with a correlation coefficient of R = 0.850. (Figure 1-5D). The 
synergy scores plotted for the trinary experiments in Figure 1-5D, though also clustered around 
zero, extended more toward 1 (synergistic) compared to the binary synergy scores (Figure 1-4E), 
which extended toward -1 (antagonistic). This is expected, in part, because the trinary 
experiments were sampled across only the low and medium dose ranges, thus, there were fewer 
instances of saturation due to platelet activation by high doses of multiple agonists. Furthermore, 
only low and medium doses of the inhibitors iloprost and GSNO were used, so their strongest 
inhibitory/antagonistic effects at 10x EC50 were not present in the trinary data (but were present in 
the binary experiments). To illustrate the predictive power of the NN-ensemble, the full time 
series plots of a random sampling of the 160 trinary conditions are shown in Figure 1-6. Full time 
series plots of all 160 trinary conditions rescaled to 0.5 are also shown in Figure A-3. For the 
trinary stimulations, the predicted calcium time traces fit the experimental data over the full time 
domain with remarkable accuracy. The trinary agonist experiments embed information about 
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platelet signaling during in vivo hemostasis, thrombosis, or bleeding. For example, during the 
early stages of vessel wall injury, platelets are activated by collagen of the damaged vessel wall 
[29] which can also generate thrombin via the extrinsic pathway (distal of tissue factor). 
Concomitantly, endothelium-derived nitric oxide and prostacyclin modulate platelet functions. 
Therefore at this early stage the platelet is mainly exposed to these three agonists: exposed 
collagen, prevailing nitric oxide and prostacyclin, while thrombin is dynamically generated. 
Soluble agonists such as ADP and thromboxane become critically important during platelet mass 
build-up (sometimes called secondary aggregation) when activated platelets release ADP from 
dense granules and generate thromboxane via COX-1. Recent in vivo and in vitro studies reveal 
that the platelets in the “core” are exposed to high levels of thrombin, while the outer shell of 
platelets see little thrombin but are especially sensitive to the presence of thromboxane [30-34]. 
 
Figure 1-5 Neural network prediction of trinary experiments. (A) Trinary experiment input conditions: all trinary 
combinations of six agonists at low and medium concentrations. (B) Measured average calcium time courses of ten 
donors in the trinary experiments. (C) The neural network trained on the PAS experiments of ten donors was able to fit 
the measured average trinary experiment calcium traces of those ten donors with a correlation coefficient of R = 0.924. 
(D) There are 160 trinary synergy scores for the trinary combination experiment. The neural networks were able to fit 
the measured average trinary synergy scores of those ten donors with a correlation coefficient of R = 0.84982. 
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Figure 1-6 Examples of NN-predicted and measured calcium time traces for the trinary combination 
experiment. Plots of 84 of the 160 conditions in the trinary combination experiment (all trinary combinations of 
agonists at two concentrations: 0.1 x EC50 and 1 x EC50). 
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2.4.3 Neural network prediction of higher order combination experiment 
The higher order test of the NN-ensemble comprised a 45-condition sampling of the full 
experimental space in equal proportions (n = 45 total combinations: 16 four-agonist, 19 five-
agonist, and 10 six-agonist conditions) (Figure 1-7A). In this subsequent higher order experiment, 
the donor pool for the generation of the PAS training dataset was expanded to 12 individuals, 10 
of which were also previously used in the prediction of trinary combination outcomes. The higher 
order experiments were an aggregate of seven experiments spanning five donors, none of whom 
were utilized in the PAS training dataset. The NN-ensemble trained only on the PAS experiments 
of 12 donors was able to predict the calcium traces of the higher order combination experiments 
with sufficiently high accuracy (R = 0.871) (Figure 1-7A-C). This higher order experiment 
represented a most challenging test of the de novo predictive capability of the neural network 
model, more so than the trinary combination experiments of Figure 1-5. With up to six stimuli 
present, this experiment triggers an extraordinary range of signaling complexity in the platelet. 
The NN-ensemble trained only on the PAS experiments was able to predict the measured synergy 
scores with a correlation coefficient of R = 0.6953 (Figure 1-7D). Compared to the synergy 
scores of the binary (Figure 1-4E) and trinary experiments (Figure 1-5D), the synergy scores of 
the higher order combination experiments tended to be more antagonistic due to saturation 
effects. Many of the measured and predicted higher ordered synergy scores were additive (S~0) 
with none being highly synergistic (all S < 0.25) which occurs for saturated signaling by only a 
few of the agonists in the mixture. During saturation, a maximal amount of calcium is released by 
IP3 or conveyed by SOCE. Therefore, the actual calcium mobilization caused by high doses of  
≥4 activating agonists was not expected to exceed the sum of calcium release due the individual 
agonists. The time series plots of all 45 conditions in the higher order combination experiment 
(Figure 1-7C and Figure 1-8) indicated that the NN-predicted time calcium time traces tended to 
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consistently under predict calcium traces involving high dose convulxin. This may be because the 
NN had not been trained on any data that involves calcium levels as high as that triggered by 
combinations of 4–6 agonists including a high dose of the potent activator convulxin. Another 
theory is that the NN may have over predicted the saturation effects in calcium responses that 
may result from combinations of multiple agonists in addition to high dose convulxin. 
Furthermore, the NN predictions underestimated the effect of iloprost and GSNO, in that 
combinations that involved those agonists tended to have calcium level predictions that were 
higher than the experimental values. However, the overall shape of almost all the predictions fits 
the experimental time traces rather well, indicating that the NN ensemble was able to capture the 
kinetics of these higher order combination experiments. There was no apparent trend in calcium 
trace prediction accuracy with increasing number of agonist (four-agonist conditions had R = 
0.82332, five-agonist conditions had R = 0.90699, six-agonist conditions had R = 0.79398). 
However, this sampling of 45 conditions was only 1.3% of the complete experimental space of 
3,402 possible conditions. 
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Figure 1-7 Neural network prediction of higher order combination experiments. . (A) Experimental input 
conditions that are a random sample (n = 45) of the complete experimental space involving four, five, and six agonists 
at low, medium and high concentrations (n = 3,402). (B) Average measured calcium time courses of seven experiments 
spanning five donors in the higher order combination experiment. (C) The neural network trained on the PAS 
experiments of 12 donors was able to fit the measured experimental calcium traces with a correlation coefficient of R = 
0.871. (D) The neural networks were able to fit the measured average synergy scores of those ten donors with a 
correlation coefficient of R = 0.6953. 
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Figure 1-8 Calcium time traces for the higher order combination experiment. Plots of the 45 conditions in the 
higher order combination experiments. 
 
2.4.4 Neural network prediction of sequential addition combination experiment 
A sequential addition experiment was done with all permutations for a two-dispense 
experiment of three agonists (ADP, convulxin and U46619) in the full dose range, i.e. 54 
conditions total (Figure 1-9A). Calcium time traces were plotted in heat map form in Figure 1-9 
B; the arrows indicate the time at which the corresponding agonists in Figure 1-9A were 
dispensed. The NN trained on the PAS experiments, in which agonist pairs were added 
simultaneously, was also able to predict the calcium output of the sequential addition experiment 
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with a correlation coefficient of R = 0.921 (Figure 1-9C). The plots of both the experimental and 
predicted time series are shown in Figure 1-10. Due to limitations of working with isolated 
platelets in vitro (requiring use within 3 hours from venipuncture), the PAS calcium readings for 
sequential addition tests required a 260 second window per column for the 24 columns of the 
384-well plate. The shorter 260 second training interval still provided accurate predictions for the 
whole 780 second window because many of the PAS calcium traces following agonist-mediated 
increases had decayed to resting levels within the 260 second training interval. This was true of 
all agonist combinations except for those involving convulxin, which generated sustained calcium 
levels in the 260 second window. Within this training interval, the PAS had captured the full 
kinetic effects of all the agonists except for convulxin. Extending the training window to 300 
seconds, where the second dispense in the sequential addition experiment had happened, would 
not confer additional information to the NN because convulxin responses would not have started 
decaying at the end of 300 seconds. Therefore, the NN trained on the PAS equipped with this 
kinetic information, in addition to crosstalk information between these six agonists from the 
pairwise conditions, was able to predict calcium responses to two agonists added sequentially 
with sufficiently high accuracy (R = 0.921), with a tendency for mild over prediction of calcium 
compared to the experimental time series. Nonetheless, the shape of the NN and measured 
calcium traces were quite similar (Figure 1-10). As expected, in conditions where convulxin was 
added first in the sequential addition experiments, the NN predicted a sustained calcium level 
instead of a slight decay in calcium response toward the end of the 780 second window, since this 
decay had not been captured in the 260 second window of the PAS experiment used in NN 
training. 
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Figure 1-9 Neural network prediction of sequential addition experiments. (A) Experimental sequential input 
conditions (n = 54) for three agonists (ADP, convulxin and U46619). (B) Measured calcium time courses of Donor Y 
in the sequential addition experiment. (C) The neural network trained on the PAS experiments of ten donors was able 
to predict the measured sequential addition calcium traces of Donor Y with high accuracy (correlation coefficient, R = 
0.921). 
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Figure 1-10 Calcium time traces for the sequential addition experiments. Plots of the 54 conditions in the 
sequential addition experiments. 
 
2.4.5 Analysis of synergy scores 
The synergy scores (Sij) reduced more than 25,000 calcium time points from a PAS 
experiment to a 135-parameter vector. Each synergy score is the most succinct first order measure 
of crosstalk between specific pairs of agonists at specific doses. The discovery of new synergistic 
and antagonistic effects between specific combinations of agonists via synergy scores can 
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motivate efforts to study the underlying biochemical mechanisms (e.g. the thrombin-thromboxane 
positive synergy is unexpected since both signal through Gq). Furthermore, the synergy score may 
underlie a drug risk (as seen with COX-2 inhibition therapy [20]), a patient-specific drug 
sensitivity or resistance. Future bottom-up models that predict the 135-parameter synergy vector 
may require interactions and pathways not explicitly represented in the currently prevailing 
platelet signaling model of Figure 1-1A. 
Synergy scores of the 10-donor, 20-experiment averaged PAS experiments were further 
analyzed to gain insight into platelet signaling. The same was done for the averaged trinary 
combination experiments and the higher order combination experiments. The mean of the 
standard deviation between donors for a given synergy score in the experiment is 0.0932 for 
binary dataset, 0.1722 for the trinary dataset, and 0.2029 for the higher order dataset. This reflects 
the variation in a given synergy score between donors. As the number of agonists involved 
increased, signaling complexity increased, resulting in larger donor variations in a given synergy 
score. 
The mean of the pairwise Sij was very close to zero (Sij = - 0.0626), and the maximum 
synergy score was 0.3461. The mean of the trinary synergy scores was slightly less negative (Sijk 
= -0.0401), and the maximum synergy score was 1, meaning that the maximum absolute synergy 
score is a synergistic one. Because trinary conditions were only sampled at the low and medium 
dose, calcium saturation from multiple high doses of agonists was avoided, therefore the synergy 
scores tended to be more synergistic. The mean of the higher order combination synergy scores 
was quite antagonistic (S = -0.3484), and the maximum synergy score was also very small (S = 
0.1085). As more agonists are involved, platelet signaling tends to reach saturation, which shifts 
the mean synergy score towards antagonism, and lowers the maximum synergy score. 
For the PAS and higher order combination experiments, the synergy score with the 
maximum magnitude was antagonistic (i.e. minimum synergy score is -1 for binary and higher 
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order experiment averages) because iloprost and GSNO are both strong inhibitors in this assay. 
For the average PAS experiment, the most antagonistic synergy score involved a high dose of 
iloprost; for the higher order experiment, it involved low dose iloprost and high dose GSNO. The 
most antagonistic synergy score for the trinary experiment is -0.5395 and it involves medium 
dose iloprost. Interestingly, the synergy metric indicates that IP receptor activation by iloprost, a 
prostacyclin mimetic, was a more potent inhibitor of calcium mobilization compared to that 
observed with the activation of guanylate cyclase via GSNO release of NO (Figure 1-4F). This 
was confirmed by the calculation of GSNO and iloprost percent inhibitions of various agonists 
used in this assay (Table 1-1 Percent inhibition of medium dose iloprost and GSNO on medium 
doses of various agonist.). It is also interesting to note that low and medium dose of GSNO 
slightly potentiated the medium dose thrombin-induced calcium release (15.73% and 13.32% 
increase respectively), consistent with previous findings that low levels of the NO donor sodium 
nitroprusside slightly potentiated thrombin-induced calcium release via store-operated calcium 
entry (SOCE), whereas higher levels inhibited thrombin-induced increases in calcium [35]. 
Similarly, in our assay, high dose GSNO inhibited the calcium release of medium dose thrombin 
(39.11% inhibition). The maximum synergy score for the PAS experiment involved a high dose 
of convulxin and medium dose of thrombin (Sij = 0.3461); the maximum of the trinary 
experiment involved medium dose convulxin, thrombin and GSNO (Sijk = 1); the maximum of the 
higher order combination experiment involved high dose ADP, medium dose thrombin, high dose 
U46619 and low dose GSNO (S = 0.1085). 
 
% inhibition by 
Iloprost 
% inhibition by 
GSNO 
ADP 71.74% 34.08% 
CVX 99.71% 18.58% 
Thrombin 76.37% -13.32% 
U46619 91.55% 67.09% 
Table 1-1 Percent inhibition of medium dose iloprost and GSNO on medium doses of various agonist. 
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In fact, four of the five strongest positive pairwise synergies involved convulxin and 
thrombin (the fifth was medium dose thrombin and U46619). Of the five strongest positive 
synergies in the trinary experiments, medium dose convulxin and thrombin were involved in all 
of them, low and medium dose GSNO was involved in two of them. Of the five strongest positive 
synergies in the higher order experiments, thrombin and U46619 were present in four of them; 
low and medium dose GSNO is involved in four of them, convulxin and thrombin were present in 
two of them. It is apparent that convulxin and thrombin used together gave the strongest 
synergistic effects, thrombin and U46619 used together also accounted for some of the strongest 
synergistic effects. For the trinary and higher order experiments, the presence of low and medium 
dose GSNO was also implicated in the highest synergy scores, and only when thrombin was 
present, which supports the previous finding that low levels of NO potentiates thrombin-induced 
calcium release via SOCE [35]. 
The synergistic effects between convulxin and thrombin were similarly found by Keuren 
et al. [27] and it was thought that thrombin-mediated influx of platelet extracellular calcium 
(through PAR-1 but not PAR-4) enhances the collagen induced procoagulant response. This may 
explain why the synergistic effects between convulxin and the PAR-1 agonist were not as 
prominent in previous PAS work that was done in the absence of extracellular calcium [19]. 
Another study that found similar synergistic effects between sub threshold concentrations of 
thrombin and GPVI showed that the synergism was independent of Src kinases and Syk [28]. As 
previously observed with EDTA-treated PRP activated by PAR-1 agonist peptide and U46619 
[20], thrombin activation of PAR-1/PAR-4 and the thromboxane mimetic U46619 were 
synergistic (Sij = 0.1127 at medium dose of thrombin and low dose U46619), and especially at 
medium doses of thrombin and U46619 (Sij = 0.1766). 
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2.4.5 Inhibition of calcium release by iloprost 
Iloprost and GSNO when used alone or together with each other had no effect on platelet 
calcium (top 9 binary conditions of Figure 1-4A-C), as expected. However, these compounds 
elevate cAMP and cGMP to attenuate calcium mobilization [36-38] and this inhibition was 
clearly seen in the calcium traces (Figure 1-6, Figure 1-8). 
Iloprost was a potent, rapid, and sustained inhibitor of convulxin activity (99.6–99.7% 
inhibition overall) (Figure 1-11B, H), indicating that IP signaling was more rapid than GPVI 
signaling. Furthermore, iloprost was more potent than GSNO in inhibiting activity of all agonists 
this assay, for example, medium dose GSNO caused only 18.6% inhibition of convulxin activity 
(Table 1-1). Convulxin caused slow platelet activation since it must multimerize GPVI to induce 
signaling [39]. During thrombin activation of PAR-1/4, the inhibition by iloprost was also rapid 
(as seen by the offset in peak calcium levels), but was incomplete initially and became more 
pronounced after approximately 25 seconds post-stimulation (Figure 1-11D, J.). Low and 
medium levels of iloprost (0.1 and 1 x EC50) resulted in similar inhibition of thrombin calcium 
release (~76.3 to 78.9% inhibition (Figure 1-11D, J). In the experiments with thrombin, iloprost 
may have a diffusive and kinetic advantage over thrombin which must cleave PAR-1/4 whereas 
iloprost simply must the bind IP receptor. A similar pattern was observed for ADP (Figure 
1-11M, N.). However, there was no offset in peak calcium levels, potentially due to similar 
diffusive and binding kinetics of these two small molecules for their respective receptors. The 
inhibition by iloprost of ADP signaling only began after ADP-induced calcium level peaked 
around 20 seconds post-stimulation (41.5% to 71.7% inhibition at 0.1 and 1 x EC50, respectively). 
During U46619 stimulation of TP receptor, the inhibition by iloprost was apparent immediately 
after dispense and increased after calcium levels peaked (~20 sec post-stimulation). Iloprost was 
slightly more potent against U46619 compared to ADP, causing 87.4% to 91.6% inhibition at 0.1 
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and 1 x EC50, respectively (Figure 1-11F, L.). Overall, iloprost was more fast-acting and potent 
against the slower signaling agonists such as convulxin (99.6–99.7% inhibition) or thrombin 
(~76–79% inhibition) that required receptor multimerization or enzymatic cleavage, compared to 
small molecules that rapidly equilibrated with their receptors such as U46619 (87–92% 
inhibition) or ADP (41–72% inhibition). Iloprost may be less active against ADP compared to 
U46619 since ADP also binds the P2Y12 receptor which antagonizes cAMP pathways (Figure 
1-1A). 
When ADP and convulxin were used simultaneously, ADP signaling dominated early 
calcium mobilization while convulxin signaling maintained sustained calcium levels. (Figure 
1-11A, G) With combined ADP/convulxin stimulation, medium dose iloprost resulted in only 
71.1% inhibition (Figure 1-11G) since it was not a complete blocker of the early signaling (at t < 
30 sec) induced by ADP. A similar trend occurred with thrombin/convulxin co-stimulation 
(Figure 1-11C, I), however, iloprost was more effective in this case (83.5% inhibition with 
medium dose iloprost, Figure 1-11I) since thrombin/convulxin co-stimulation elevated calcium 
relatively slowly. When the weaker agonist U46619 (compared to ADP) was used with 
convulxin, iloprost remained a very potent inhibitor (98.9% inhibition with medium dose iloprost, 
Figure 1-11E, K). 
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Figure 1-11 Analysis of iloprost inhibition effects 
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2.4.6 Range of individual neural network prediction and donor responses 
The range (i.e. intradonor variation) of individual NN predictions over 10 to 12 donors 
for single and pairwise agonist conditions (Figure 1-12) was comparable to the experimental 
observations, as expected for NNs trained exactly on those conditions (Figure 1-12A, B). 
Similarly, the range of NN predictions for trinary agonist conditions matched the range for the 
experimental values as well (Figure 1-12C). The range of the higher order NN predictions (≥ 4 
agonists) was somewhat larger than the range observed in the corresponding individual 
experiments (Figure 1-12D–F). Clearly for ≥ 4 agonists, the signaling pathways span a very 
complex platelet biology beyond the dimensionality of the pairwise training data. Nonetheless, 
the range of the NN predictions reflected to a large degree the range of the experiment itself. For 
example, the range of the NN predictions in Figure 1-12E was smaller than the range in Figure 
1-12D; the same trend was reflected in the range of the actual experiments. Furthermore, for ≥ 4 
agonists, the experimental data comprises seven experiments spanning five donors, whereas the 
NN used in training spanned 12 donors, which in part explains why simulation ranges were larger 
than ranges of experimental observations. The NN range over all 120 NNs in Figure 1-12D was 
larger than the experimental ranges, potentially reflecting donor variation but more importantly 
reflecting the difficulty of predicting higher dimensional responses. Despite the substantial range 
of individual NN predictions for the four-agonist condition depicted in Figure 1-12D, the mean of 
the NN predictions predicted the mean response of the actual experiments, a benefit of the NN-
ensemble approach for predicting a pooled population dynamic. 
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Figure 1-12 Range of individual neural network responses and donor responses 
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2.5 Discussion 
 
While the full complexity of receptor mediated signaling in platelets extends well beyond 
the known pathways indicated in Figure 1-1A, a top-down approach using pairwise agonist 
scanning (PAS) provides an efficient data-driven method to predict platelet function. By using 
data obtained from multiple donors and training multiple NNs for each donor, a NN-ensemble 
(Figure 1-3) allowed accurate prediction of 135 binary stimulations and 135 synergy parameters 
(Figure 1-4). The synergy vector composed of the 135 synergy parameters is an experimentally 
measured human platelet phenotype (healthy adult male and female) that is fully predicted by the 
NN-ensemble. Furthermore, the NN-ensemble provided suitable prediction beyond the binary 
training set to predict trinary responses (Figure 1-5, Figure 1-6), higher ordered responses 
(Figure 1-7, Figure 1-8), and response to sequential stimuli (Figure 1-9, Figure 1-10). The major 
components of hemostasis and thrombosis that regulate platelet activation state are now 
quantitatively captured in the NN-ensemble. For large scale simulation of blood function, a user 
may specify or calculate any combination of the six agonists at different concentrations to 
produce a dynamic platelet calcium response representative of a healthy human donor. 
The NN is able to do this mainly because individual and pairwise interactions dominate platelet 
calcium signaling crosstalk in this assay, and because all single agonists are sampled across each 
of their full dose ranges [20]. An ordinary differential equation (ODE) model describing the 
calcium mobilization mediated by all six PAS agonists would likely require an estimated >500 
kinetic parameters, many of which are unavailable [20]. 
From the perspective of a data-driven and top-down approach, NNs have proven quite 
robust and well matched to PAS data sets. Also NNs are ideal for multiscale simulations that 
involve crosstalk between receptors. However, NNs are not mechanistic models for identification 
or quantification of basic biochemical mechanisms. The full calcium dataset generated in this 
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work can also facilitate future mechanistic model building. For example, future mechanistic 
models of receptor signaling and crosstalk should be testable against the 135-parameter synergy 
map we measured. Such mechanistic models should account for RGS proteins, PKC, 
cAMP/PKA, cGMP/PKG, and phosphodiesterase pathways, as well as receptor desensitization 
pathways including ITIM/Shp2 phosphatase, receptor internalization, and receptor shedding 
pathways, along with regulation of store operated calcium entry. Improved predictive capability is 
not necessarily an outcome of constraining of NN nodes and linkages to a preconceived reaction 
topology as in Figure 1-1. 
The calcium experiments that the NN was trained on included the contributions of SOCE 
because Apixaban was used in place of a calcium chelator as an anticoagulant. The effect of 
autocrinic effects by ADP and thromboxane secretion, however, were not significant in the PAS 
assay due to the dilute conditions of the assay (Figure A-2). Such autocrinic effects however are 
naturally captured in multiscale simulations that include convection-diffusion of soluble agonists 
[24]. Other important inside-out signaling downstream of calcium mobilization, such as integrin 
engagement, granule release, shape change, and phosphatidylserine exposure can be simulated by 
incorporating the calcium model into a larger fine or coarse-grain model. For example, in Flamm 
et al. (2011), NN were trained via PAS using calcium-containing PRP and then used to predict 
platelet deposition rates on collagen in the absence of thrombin by accounting for platelet 
signaling in response to laboratory analogs of collagen, ADP, thromboxane, and prostacyclin 
[24]. Alternatively, the PAS methodology has also been adapted by Jaeger et al. [40] for flow 
cytometry instead of calcium measurements, so as to quantify inside-out signaling events such as: 
integrin αIIbβ3 activation, P-selectin exposure, and PS exposure using PAC-1, anti-P-selectin 
antibody, and annexin V, respectively.  
The NN ensemble trained only on pairwise data was able to predict the calcium output of 
higher order agonist combination experiments with reasonably high accuracy. This was 
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potentially due to a sparsity-of-effects principle: a system is largely dictated by main effects and 
lower order interaction [41]. Adding trinary conditions to the training data might theoretically 
improve prediction accuracy when it comes to higher order combinations. The improvement in 
accuracy should be a measure of the information content of trinary data. In separate studies, we 
tested the utility of adding trinary stimulation data to the PAS training set in order to enhance the 
predictive capability of the NN-ensemble. Trinary data were incorporated into the NN ensemble 
in 3 different ways, each time controlling for the number of NNs in the ensemble. The first set of 
trinary data collected comprised 160 trinary combinations of all six agonists at only low and 
medium concentrations, repeated on 10 donors. Adding this trinary data reduced the higher-order 
combination prediction accuracy from R = 0.824 to R = 0.784, and synergy score accuracy 
decreased from 0.66936 to 0.66145. The second set of trinary data collected comprised 27 
combinations of only three agonists (ADP, convulxin, U46619) in the full dose range, repeated on 
eight donors. Adding this trinary data did not substantially affect the prediction accuracy (calcium 
trace accuracy from R = 0.810 to R = 0.806, and synergy correlation from R = 0.66367 to R = 
0.68387). The third set of trinary data collected was an unbiased, random sampling (n = 54) of the 
complete trinary space done on a single donor, who was not part of the original PAS dataset. 
Adding this trinary data increased prediction accuracy of the time courses (from R = 0.871 to R = 
0.906), but reduced the accuracy of synergy scores prediction from R = 0.6953 to R = 0.53925. 
We conclude that incorporating a randomly sampled trinary dataset can moderately increase 
prediction accuracy, whereas adding a biased sample of the trinary space does not increase 
accuracy. In fact, adding a sample of the trinary space that does not span the full dose range may 
reduce accuracy. However, even in the best of the three scenarios tested, adding trinary data to 
the PAS training dataset did not substantially improve accuracy. 
The 120-NN ensemble (R = 0.87134, mean-squared error, MSE = 0.0129) was more 
accurate than the average individual NN within the ensemble (R average = 0.6566, MSE average 
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= 0.0501) in predicting the calcium traces of higher order combination experiments. Even though 
the most accurate individual NN in the 120-NN ensemble (R = 0.91391, MSE = 0.0092) was 
more accurate than the ensemble itself, its prediction output was significantly noisier, and its 
synergy score prediction accuracy was much lower (R = 0.6953 to R = 0.4609). The ensemble 
approach reduced variances in prediction output, increased accuracy above the average NN in the 
120-NN ensemble, consistent with previous findings [42], and is generally thought to be more 
robust [43-46]. Ensemble pruning is often used to eliminate individual models from the ensemble 
based on certain criteria so as to improve the new ensembles predictive ability[46]. Using the 
interquartile range (IQR) outlier detection method, eight high outliers spanning seven different 
donors were identified in the mean-squared error (MSE) measurements of each of the 120 
individual NNs. Removing the eight most inaccurate individual NNs from the ensemble did not 
improve the ensemble accuracy (R-value improved slightly from 0.87134 to 0.87768, but MSE 
increased slightly from 0.0129 to 0.0148, synergy score R decreased slightly from 0.6953 to 
0.68632, and noise in ensemble predictions increased). Diversity of the models (in this case 
originating from the different random initial weights generated at the beginning of each NN 
training) comprising an ensemble is important for accuracy and robustness [47-49]. To increase 
diversity, heterogeneous ensembles may be used instead; for example, changing the training 
parameters of select individual NNs or incorporating into the NN-ensemble regression models 
other than NNs [46]. 
We found that the NN-ensemble was able to account for the dynamics and magnitude of 
one pathway relative to that of another. Iloprost was a very potent antagonist in this assay. In 
vivo, prostacyclin activates IP to increase cAMP and cGMP-dependent protein kinases pKA and 
pKG. Both pKA and pKG phosphorylate RGS18 (a G-protein regulator), which eventually turns 
off Gq-signaling, the main activation pathway for U46619 and thrombin (via PAR-1) [50]. ADP 
signaling through P2Y1 also goes through Gq-signaling. However, ADP also signals through the 
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P2Y12 receptor, which involves the Gi protein (Figure 1-1A).Thrombin signaling through PAR-4 
can go through either Gq or Gi. The existence of alternate signaling routes (through Gi) explain 
why iloprost inhibition is markedly less potent for ADP, and slightly less effective for thrombin 
as well. Furthermore, signaling through the Gi protein inhibits the rise in adenylate cyclase 
(precursor of cAMP which decreases intracellular calcium levels). As expected from studies of 
“coated” platelets [51] and studies with similar findings [27, 28], convulxin and thrombin were 
quite synergistic in the PAS assay. Additionally, thrombin and TP receptor signaling were 
somewhat synergistic, consistent with previous findings [20, 24]. In future work, the NN-
ensemble can be incorporated in multi-scale and hierarchical simulations of bleeding or clotting 
with linkages to vascular pathophysiology. While exogenously added thrombin was used in PAS, 
not all of this thrombin may reach the platelet due to antithrombin. This may right shift the 
thrombin potency [52]. Iloprost and GSNO were also included in this assay to recapitulate 
endothelial-derived prostacyclin and nitric oxide effects on platelet function. The development of 
a healthy human platelet calcium calculator can enable various applications such as predicting 
thrombosis or hemostasis under flow condition or extracting information from in vitro 
diagnostics, potentially using platelets from patients with cardiovascular disease risks. 
Furthermore, the generalizability of the neural network may be quickly improved, by 
training the ensemble NN on more donors. On the other hand, the human platelet calcium 
calculator may also be easily and quickly tailored for a specific individual by using NN trained on 
PAS data of only that donor. It would not be easy for the equivalent to be done for a mechanistic 
ODE model, as each of the many kinetic parameters has to be re-optimized for the new data.  One 
of the potential applications for this calculator is for use in a multiscale simulation of thrombus 
formation. Since calcium is the central node of platelet signaling, the healthy human platelet 
calcium calculator can enable simulation of physiologic scenarios where agonist concentrations 
vary continuously, which is difficult to obtain experimentally. For example, Figure 1-13 depicts 
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three theoretical phases that occur in succession for platelet activation during injury, the 
theoretical agonist concentration experienced by platelets at each phase, as well as corresponding 
simulation of calcium levels for each phase.  The first phase represents the early phase of the 
coagulation pathway: a monolayer of platelets is exposed continuously to collagen surface on the 
injured endothelium.  This can be represented in the PAS assay as a steady level of convulxin.  
The resulting simulation captures the effects of iloprost and GSNO, analogs of PGI2 and nitric 
oxide, which are also released by the endothelium during clotting. The NN predicts a sustained 
intracellular mobilization in the studied time frame of 0 - 4 minutes. The second phase represents 
the autocrinic signaling phase: Calcium mobilization from phase 1 prompts dense granule 
secretion, releasing ADP, which further prompts thromboxane generation. Calcium mobilization 
also causes phosphatidylserine exposure and thus thrombin production. This is illustrated in the 
agonist concentration profiles. As a result the calcium levels peak slightly after ADP release, but 
are in general lower and less sustained than before. Phase three represents the late phase of 
clotting. ADP levels (released from platelet dense granules previously) decline; thromboxane 
levels increase slightly from phase but eventually declines. Thrombin levels continue to rise from 
phase 2 to a higher level than thromboxane because of contribution from both the intrinsic and 
extrinsic pathway, but declines eventually. The resulting calcium prediction has two peaks: one 
when both thrombin and thromboxane levels are rising and then a later, smaller peak when 
thrombin peaks but platelet-derived thromboxane and ADP have been depleted. In general, while 
both PGI2 and NO act to inhibit calcium mobilization, the effect of PGI2 is more pronounced and 
sustained. This agrees with Radomski et al., who found that the IC50 of NO was about two orders 
of magnitude higher than that of PGI2 for platelet aggregation when stimulated by ADP, collagen, 
thrombin and U46619 [36]. 
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Figure 1-13 Simulations of platelet calcium levels based on theoretical agonist distribution in vivo. (A) 
Progression of platelet activation in vivo upon endothelial injury, defined in three phases. (B) The top row represents 
agonist concentrations in the three defined phases. Concentrations are mapped between 0 and 1 (0 being not present 
and 1 being 10xEC50). The bottom row represents the corresponding predicted calcium time traces. 
 
All the above mentioned attributes of the calcium calculator, especially its ability to 
simulate physiologic scenarios where agonist concentrations vary continuously, makes it ideal for 
incorporation into a larger multiscale model of clotting. Such a model can have further 
applications such as predicting thrombosis or hemostasis under flow condition. In fact, in a paper 
currently in preparation by Lu et al. [53],  a multiscale approach was developed with a goal of 
patient-specific simulation of thrombosis from single platelets to the whole clot, to account for: 
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platelet signaling (neural network trained by pairwise agonist scanning, PAS-NN), platelet 
positions (lattice kinetic Monte Carlo, LKMC), wall-generated thrombin (76-species ODE 
model), multicomponent convection-diffusion (PDE), and flow over a growing clot (lattice 
Boltzmann). At all times, intracellular calcium was calculated for each platelet by the PAS-NN 
(also known as human platelet calcium calculator) developed here, in response to its unique 
exposure to local collagen, ADP, thromboxane, and thrombin. When compared to microfluidic 
experiments of human blood clotting on collagen/TF under flow driven by constant pressure drop, 
the model accurately predicted clot morphology and growth with time. For TF at 0.1 and 10 
molecule/μm2 and initial wall shear rate of 200 s-1, the occlusive blockade of flow for a 60-μm 
channel occurred relatively abruptly at 500 and 400 seconds, respectively, in both experiment and 
simulation. Prior to occlusion, intrathrombus concentrations reached 50 nM thrombin, ~1 μM 
thromboxane, and ~10 μM ADP, while the wall shear rate on the rough clot surface peaked at 
~500-1000 s
-1 
[53]. This demonstrates the utility and universality of the human platelet calcium 
calculator in predicting physiologic events.  
 
2.0 Downregulation of platelet GPVI signaling following thrombin 
stimulation 
3.1 Abstract 
 
Activating platelets with thrombin in platelet-rich plasma (PRP) caused an attenuation of 
convulxin-induced calcium mobilization when convulxin was added to PRP 480 seconds later. 
This attenuation effect was not observed when ADP and thromboxane analog, U46619 was used 
in place of thrombin. The attenuation effect increased with higher doses of thrombin and longer 
times between initial thrombin dispense and later convulxin addition. When PAR-1 and PAR-4 
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receptor agonists (AYPGKF and SFLLRN) were used instead of thrombin for the initial dispense, 
the subsequent convulxin-induced calcium response was unaffected, supporting thrombin’s 
unique role in causing attenuation of subsequent convulxin-induced calcium mobilization. 
Thrombin, unlike ADP, U46619 or the PAR-1 and PAR-4 receptor agonists, is able to polymerize 
fibrinogen into fibrin. When GPRP was added to prevent polymerization of fibrin, initial platelet 
activation by thrombin did not result in attenuation of convulxin- induced calcium mobilization as 
it did when GPRP was not present. This experiment was repeated using a mixture of washed 
platelets and fibrinogen monomers instead of PRP, resulting in similar results as before: the 
addition of thrombin to fibrinogen mixture caused an attenuation of convulxin-induced calcium 
mobilization when convulxin was added to the mixture 480 seconds later, but not when GPRP 
was added to inhibit fibrin polymerization. The presence of polymerized fibrin also reduced 
platelet deposition in a microfluidic assay on a collagen surface. These results suggest that 
polymerized fibrin binds to and downregulates platelet GPVI function.  
3.2 Introduction 
 
Platelet GPVI is an immunoglobulin superfamily receptor expressed on platelet surface in 
association with the FcRγ chain (Fc receptor γ chain) [16]. There are approximately 3,700 copies 
of GPVI on a platelet [54]. When GPVI is bound by collagen, GPVI receptors cluster, resulting in 
Src kinase-dependent tyrosine phosphorylation of the FcRγ chain immunoreceptor tyrosine-based 
activation motif [16]. This leads to the signaling protein recruitment (e.g. the Src kinase, the 
tyrosine kinase Syk, PLCγ2, phosphoinositide 3-kinase (PI3K) and MAPKS[55, 56]), all of which 
set of a signaling pathway, triggering calcium mobilization within platelets and initiating the 
inside-out activation of the integrin αIIbβ3 and the release of the secondary soluble mediators, such 
as ADP and thromboxane (TxA2)[57]. This leads to platelet aggregation mediated by fibrinogen 
binding between platelet integrins αIIbβ3 and results in thrombus formation [57]. GPVI has many 
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activating ligands including collagen, collage-related peptide (CRP), convulxin [6, 7]. Recently it 
has also been found that GPVI interacts with fibronectin [58], vitronectin [59] and laminins [60], 
which, in addition to GPVI-collagen interaction might contribute to the role of GPVI in thrombus 
formation.  
Platelet GPVI has been highlighted recently as a desirable target for antithrombotic drug 
development [61-65] because it’s blockade and downregulation in in vitro experiments, as well as 
functional GPVI deficiency in animal models have been shown to impair thrombus formation, but 
not disrupt hemostasis [62, 65-67]. Compared to the current standard treatment of dual 
antiplatelet therapy combining aspirin with an ADP receptor antagonist (Clopidogrel, prasugel, 
tricagelor), which may be effective but increases bleeding risk [68, 69], anti-GPVI treatment 
could have the potential to be both effective yet safe. One option is to target events downstream 
of GPVI activation, such as GPVI-induced calcium mobilization. In the following experiments, 
polymerized fibrin (as a result of added thrombin), has been shown to downregulate convulxin-
induced GPVI calcium mobilization. Understanding the mechanism underlying this observation 
could be important in developing a viable GPVI-targeted antithrombotic therapy. Furthermore, 
since elevated soluble fibrin levels have been implicated in trauma and disseminated intravascular 
coagulation (DIC) [70-73], understanding the mechanism behind the downregulation of GPVI 
signaling by polymerized fibrin has clinical importance. 
The fact that GPVI is a receptor for polymerized fibrin was recently discovered [16, 18]. 
According to those recent studies, GPVI binding to fibrin increases platelet procoagulant activity 
[16], amplifies collagen-independent thrombin generation and platelet recruitment at clot surface 
[18], and eventually contributes to thrombus growth and stabilization [16, 74]. However, the 
mechanism of interaction of GPVI and fibrin is not clear, especially as it pertains to GPVI-
mediated calcium signaling. Furthermore, the many procoagulant properties that fibrin-GPVI 
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binding reportedly confers depend on that interaction’s ability to promote thrombin generation. 
The focus of the following experiments will be on the impact that GPVI-fibrin interaction has on 
GPVI-mediated calcium mobilization in apixaban-treated conditions (apixaban binds specifically 
to factor Xa to prevent endogenous thrombin production).  
3.3 Materials and Methods 
 
3.3.1 Platelet Calcium Assays 
Whole blood was drawn by venipuncture from healthy donors according to the University 
of Pennsylvania Institutional Review Board guidelines (protocol number: 805305), into a syringe 
containing apixaban with a final concentration of 250 nM. Donors self-reported to be free of any 
medications or alcohol use for three days prior to the blood draw. Female donors self-reported to 
not using oral contraceptives. 
Platelet rich plasma (PRP) was then obtained by subjecting the whole blood sample to 
centrifugation at 120g for 12 minutes. Then, 2 ml of PRP was incubated with a vial (single 
microplate size) of Fluo-4 NW dye mixture reconstituted with 7.8 ml of HEPES buffered saline 
(HBS, sterile filtered 20mM HEPES and 140mM NaCl dissolved in deionized water, adjusted to 
pH7.4 with NaOH ) and 200 µL of 77 mg/ml reconstituted probenecid for 30 minutes. At this 
stage, for conditions involving GPRP and/or vorapaxar, GPRP and/or vorapaxar was added and 
incubated along with the dye in the PRP mixture to give a final concentration of 500 µM and 100 
nM respectively. Meanwhile, a 384-well plate containing platelet agonists (called the ‘agonist 
plate’) was assembled. The agonists included thrombin, ADP, U46619 (a thromboxane analog), 
SFLLRN and AYPGKF (PAR-1 and PAR-4 receptor agonists), as well as convulxin (a collagen 
analog). After incubation with dye, the PRP was dispensed into a 384-well plate (called the ‘read 
plate’). Both the agonist and read plate were loaded into a Molecular Devices FlexStation 3, a 
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fluorescence reader with auto-pipetting capabilities. Agonists were dispensed to a column of 
wells containing the PRP, where well fluorescence F(t) was read and normalized by the pre-
dispense baseline. For conditions involving two dispenses, 10 L of agonist was first added to 30 
L of PRP in each well, and at a later specified time, 10 L of convulxin was first added, giving a 
final volume of 50 L. For conditions involving only one dispense, 20 L of agonist was added 
to 30 L of PRP in each well, giving a final volume of 50 L. In each well, the final 
concentration of PRP after agonist addition was 12% PRP by vol., and the volume of calcium dye 
was 15 L (30% dye by vol.). The fluorescence was read for 20 seconds before first dispense, and 
readings were taken in intervals of 2.5 seconds (EX/EM, 485 nm/525 nm).  For all experiments, 
the entire plate was read, column-wise, in under 90 minutes. In previous tests using indomethacin 
(Sigma-Aldrich) to block COX-1 and apyrase (Sigma-Aldrich) to degrade released ADP, there 
was no evidence for autocrine signaling in the dilute PRP conditions of the experiment [75].  
For the calcium assay involving washed platelets (Figure 2-5), washed platelets were first 
obtained by subjecting whole blood to centrifugation at 200g for 14 minutes to obtain PRP. Then, 
2 ml of PRP was incubated with a vial (single microplate size) of Fluo-4 NW dye mixture 
(Invitrogen) reconstituted with 5 ml of HBS and 200 µL of 77 mg/ml reconstituted probenecid 
(Invitrogen) for 30 minutes. After incubation, Tyrode’s buffer containing PGE1 (1 μM) and 
apyrase (1 U/mL) was added to the PRP mixture in a volume ratio of 1:5. The mixture was then 
spun at 1200g for 14 minutes to obtain a platelet pellet after removing the resulting supernatant. 
The platelet pellet was then resuspended in 1.1ml of HBS to obtain a washed platelet suspension. 
Then human research grade fibrinogen was added to the washed platelets mixture for a final 
concentration of 500nM. For the condition involving GPRP, GPRP was also added at this stage. 
After 10 minutes of incubation, the washed platelet and fibrinogen mixture was then dispensed 
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into the read plate.  Then both read plate and prepared agonist plate were loaded onto the 
fluorescence reader and read in the same manner as all other calcium assays.  
Apixaban was obtained from SelleckChem, Fluo-4 NW dye and probenecid from 
Invitrogen, ADP, GPRP, PGE1 and apyrase from Sigma-Aldrich, convulxin from Pentapharm, 
thrombin and human research grade fibrinogen from Haematologic Technologies Inc., PAR-1 and 
PAR-4 agonists from Bachem, U46619 from Tocris Bioscience, and vorapaxar from Ryan 
Scientific. 
 
3.3.2 Microfluidic assays 
L of GPRP (or HBS for control condition) was added to 19.7 L of fluorescent 
fibrinogen from human plasma (Alexa Fluor® 647 conjugate), and allowed to incubate for 15 
minutes. Then 2.3 L of thrombin was added (final concentration 2.5 nM) was added to the 
mixture to induce polymerization of fibrinogen into fibrin. After 300 seconds, 2 L of D-
Phenylalanyl-prolyl-arginyl Chloromethyl Ketone (PPACK) was added (final concentration 
100 M) to stop thrombin activity. The mixture was then diluted 10 fold into whole blood that 
was drawn via venipuncture into PPACK (100 M) and apixaban (1 M). The resulting 
fibrinogen/fibrin solutions were diluted by a factor of 10 in PPACK/apixaban-treated whole blood 
with either 5 mM GPRP or HBS then perfused through an 8-channel microfluidic device at 200s
-1
 
over a collagen surface. The resulting platelet and fibrin fluorescence were recorded once a 
minute for 6 minutes. The microfluidic device preparation and perfusion was performed by 
another Diamond lab member, Brad Herbig. 
Fluorescent fibrinogen was obtained from Thermo Fisher Scientific, PPACK was 
obtained from Haematologic Technologies Inc. 
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3.4 Results 
 
3.4.1 Thrombin uniquely attenuates subsequent platelet calcium response to convulxin 
When thrombin is first added to PRP and convulxin (a collagen analog) is added 480 
seconds afterward, the calcium signal in response to convulxin is significantly reduced compared 
to the control condition in which PRP was not first activated by thrombin (Figure 2-1A). This 
phenomenon was apparent at all low to medium doses of thrombin (1 nM to 10 nM or 0.5 to 5 x 
EC50) (Figure 2-1A). However, this phenomenon was not observed when ADP or U46619 was 
added instead of thrombin. When ADP was added instead of thrombin, very low dose of ADP (10 
nM or 0.01 x EC50) did not affect subsequent calcium response to convulxin compared to the 
control condition (Figure 2-1B). Low to medium doses of ADP (100 nM to 1 μM or 0.1 to 1 x 
EC50) very slightly increased subsequent calcium response to convulxin (Figure 2-1B). High dose 
of ADP (10 μM or 10 x EC50) resulted in noticeable reduction in subsequent platelet calcium 
response to convulxin, but not to the extent seen in the case of thrombin (Figure 2-1B). When 
U46619 was added in place of thrombin, very low to medium doses of U46619 (10 nM to 1 μM 
or 0.01 to 1 x EC50) did not affect subsequent calcium response to convulxin compared to the 
control condition (Figure 2-1C). Similarly, as seen in the case of ADP, high dose of U46619 (10 
μM or 10 x EC50) resulted in a detectable reduction in subsequent platelet calcium response to 
convulxin, but not to the extent caused by any dose of thrombin (Figure 2-1C).  
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Figure 2-1 Different effects in attenuation of subsequent platelet convulxin calcium response by thrombin 
compared to ADP and thromboxane. (A) Platelet activation by thrombin causes a significant reduction in subsequent 
convulxin-induced calcium response 480 seconds later. This effect is seen for all low to relatively high doses of 
thrombin (1 – 10nM). (B) Platelet activation by ADP does not significantly attenuate subsequent convulxin-induced 
calcium response. Lower doses of ADP (10nM – 1uM) slightly enhance subsequent convulxin response. The high dose 
of ADP (10uM) slightly attenuates subsequent convulxin response. (C) Platelet activation by the thromboxane analog, 
U46619, also does not significantly attenuate subsequent convulxin-induced calcium response. Lower doses of ADP 
(10nM – 1uM) have no effect on subsequent convulxin response. Similarly to ADP, the high dose of U46619 (10uM) 
slightly attenuates subsequent convulxin response. 
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3.4.2 Extent of attenuation of convulxin calcium response increases with incubation time and 
thrombin dose 
When convulxin is added after incubation time, tinc = 150, 210 and 335 seconds after low 
dose thrombin (1 nM or 0.05 x EC50) is first added to PRP, the calcium signal in response to 
convulxin is comparable to the control condition in which PRP was not first activated by 
thrombin (Figure 2-2A). When incubation time increases to 480 seconds, subsequent calcium 
response to convulxin decreases significantly, and is decreased further when incubation time 
increases to 600 seconds (Figure 2-2A). When a slightly higher dose of thrombin (2 nM or 0.15 x 
EC50) is first added to PRP, subsequent calcium response to convulxin is not attenuated until 
incubation times increase to 210 seconds or higher (Figure 2-2B). Similarly, the extent of 
attenuation of convulxin calcium response generally increases with longer incubation times 
(Figure 2-2B). In general, a minimum incubation time must be met for noticeable attenuation of 
subsequent calcium response to convulxin, after which increasing incubation times tend to 
increase the extent of attenuation. This observed trend is illustrated in Figure 2-2C. The time 
needed to reach 95% of peak convulxin calcium response for the control condition is t95 = 86.7 
seconds. Subsequent convulxin-induced calcium fluorescence intensity at t95 = 86.7 seconds for 
all conditions in Figure 2-2A and Figure 2-2B were measured and expressed as a percentage of 
the 95% peak convulxin response of the control condition with no thrombin pre-treatment, in 
Figure 2-2C. The resulting plot was fitted with a Hill function (Figure 2-2C). When platelets are 
pre-treated with the lower thrombin dose (1nM), reduction of convulxin response starts after only 
after approximately 450 seconds and drops rapidly to the maximum reduction (~80%) after 
approximately 500 seconds. At the higher thrombin dose (2nM), reduction of convulxin response 
starts much earlier (~200s) and reaches the maximum reduction (~80%) after approximately 220 
seconds (Figure 2-2C). Perhaps because both doses of thrombin used were low (1 nM and 2 nM), 
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the dose of thrombin does not appear to influence the maximum extent of reduction. However, a 
slightly higher dose of thrombin (2 nM vs. 1 nM) reduced the incubation time needed to observe a 
significant reduction in subsequent convulxin response. The steep shape of the Hill function for 
both conditions also indicates a switch-like minimum threshold in incubation time needed for 
significant attenuation of subsequent convulxin response.  
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Figure 2-2 Effect of time and dose of thrombin in attenuation of subsequent platelet convulxin calcium response. 
(A) When platelets are first activated by low dose thrombin (1nM), the extent of reduction of subsequent platelet 
convulxin increases with time. When convulxin is introduced up to 335 seconds after thrombin, convulxin response is 
comparable to the control condition. When time between the two dispenses (incubation time) increases to 480 seconds 
and beyond, the reduction in convulxin response is significant, and increases with higher incubation times. (B) When 
platelets are first activated by a slightly higher dose (2nM), notable reduction of subsequent platelet convulxin starts at 
shorter incubation times (210 seconds and beyond) compared to (A). The extent of convulxin response reduction 
increases with increasing incubation times. (C) The time needed to reach 95% of peak convulxin response for the 
control condition is t95 = 86.7 seconds. Convulxin-induced calcium fluorescence intensity at t95 = 86.7 seconds was 
measured and calculated as a percentage of the 95% peak convulxin response of the control condition with no thrombin 
pre-treatment for all conditions in (A) and (B). The resulting plot was fitted with a Hill function. 
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3.4.3 Activating PAR-1 and PAR-4 do not result in attenuation of subsequent platelet calcium 
response to convulxin 
Even though thrombin signals through PAR-1 and PAR-4 receptors, when PAR-1 and 
PAR-4 agonists (SFLLRN and AYPGKF) are first added instead of thrombin, subsequent platelet 
calcium response to convulxin is unaffected compared to the control condition (Figure 2-3A). 
This suggests that thrombin plays a unique role. When vorapaxar, a PAR-1 specific inhibitor is 
added, calcium signaling in response to thrombin is blocked (Figure 2-3B). This indicates that in 
these platelet calcium assays, thrombin-induced calcium mobilization is dependent on PAR-1 and 
cannot solely happen through PAR-4 signaling. Interestingly, when thrombin is first added to 
PRP incubated with vorapaxar, subsequent calcium response to convulxin is also attenuated to the 
same extent as the condition without vorapaxar (Figure 2-3C). This indicates that the convulxin 
response attenuation effect can happen solely through PAR-4 signaling. 
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Figure 2-3 Platelet convulxin calcium response attenuation effect is not observed by pretreatment with PAR-1 
and PAR-4 agonists(A) Despite thrombin signaling through PAR-1 and PAR-4, platelet activation by PAR-1 and 
PAR-4 specific agonists (SFLLRN and AYPGKF) does not reduce subsequent convulxin response as thrombin does, 
and results in convulxin response levels similar to the control condition. (B) Vorapaxar, a PAR-1 specific antagonist, 
blocks thrombin-induced calcium signaling. (C) The convulxin calcium response attenuation after thrombin pre-
treatment effect is still apparent when Vorapaxar, a PAR-1 specific antagonist is present. 
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3.4.4 Fibrin plays an essential role in attenuation of subsequent platelet calcium response 
When thrombin is first added to PRP incubated with GPRP, which blocks polymerization 
of fibrinogen into fibrin, subsequent calcium response to convulxin is unaffected compared to the 
control condition where thrombin was not first added (Figure 2-4A). This indicates that fibrin is 
essential for the thrombin-induced attenuation of subsequent convulxin response. Unlike 
thrombin, ADP does not induce polymerization of fibrinogen into fibrin. Therefore, as expected, 
when the experiment in Figure 2-4A is repeated with ADP instead of thrombin, GPRP does not 
affect subsequent calcium response to convulxin (Figure 2-4B). This indicates that thrombin-
induced fibrin generation may be responsible for attenuation of subsequent calcium response to 
convulxin. It is also interesting to note that in all calcium responses to thrombin, the calcium 
signal trends upward. However, in cases with GPRP present, thrombin induced calcium 
mobilization is transient and eventually returns to baseline (Figure 2-4C).  
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Figure 2-4 Fibrin plays important role in platelet convulxin response attenuation effect (A) GPRP inhibits 
fibrinogen polymerization by directly binding the fibrinogen polymerization sites. The downregulation of platelet 
calcium GPVI signaling by thrombin was not observed when GPRP was present. (B) Because platelet activation by 
ADP does not cause fibrinogen to polymerize into fibrin, GPRP has no effect on subsequent convulxin response. (C) In 
thrombin-induced platelet calcium signaling, calcium levels trend upward after peak. However, in the presence of 
GPRP, thrombin-induced calcium signaling is transient and returns to baseline levels after the peak. 
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3.4.5 Platelet convulxin response attenuation effect is reproduced in washed platelets and 
fibrinogen environment 
Washed platelets were incubated with human research-grade fibrinogen (500 nM) with 
and without GPRP for 10 minutes before the calcium fluorescence reading (Figure 2-5). Unlike 
the experiments in Figure 2-1 to Figure 2-4 that were done in PRP, in this experiment involving 
only washed platelets and fibrinogen, antithrombin is not present. Nonetheless, a low dose of 
thrombin (1nM) similarly attenuated subsequent convulxin response after 480 seconds (Figure 
2-5).  Also, similar to experiments involving PRP, the condition involving GPRP had subsequent 
convulxin response levels similar to the control condition where no thrombin was added (Figure 
2-5). This indicates that fibrin, rather than antithrombin or other components of plasma, is 
responsible for the attenuation of subsequent calcium response to convulxin after platelet pre-
treatment with thrombin.   
 
Figure 2-5 Platelet convulxin response attenuation effect is reproduced in washed platelets and fibrinogen 
mixture. (A) Schematic of work flow. (B) In a washed platelet and fibrinogen (500 nM) mixture, low dose of thrombin 
(1 nM) at 480 seconds incubation time significantly attenuated subsequent convulxin response, as seen in Figures 3-1 to 
3-4 in PRP.   
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3.4.6 Presence of fibrin reduces platelet adhesion on collagen in microfluidic assay 
Fluorescent fibrinogen was incubated in either 5mM GPRP (to inhibit fibrin formation) 
or HBS (control condition) for 10 minutes. Following incubation, 2.5nM thrombin was added to 
both conditions. After 300s, thrombin was quenched with 100µM PPACK in order to stop 
thrombin-induced fibrin polymerization. The resulting fibrinogen/fibrin solutions were diluted by 
a factor of 10 in PPACK/apixaban-treated whole blood (PPACK quenches thrombin and apixaban 
prevents endogenous thrombin production by binding to factor Xa) with either 5 mM GPRP or 
HBS then perfused through an 8-channel microfluidic device at 200s
-1
 over a collagen surface. As 
seen in Figure 2-6, as expected, 5mM GPRP (which inhibits polymerization of fibrinogen into 
fibrin) decreased fibrin deposition compared to the HBS control. Interestingly, in Figure 2-6B, 
GPRP increased platelet deposition on the collagen surface after 60s. This suggests that the fibrin 
in the control condition resulted in reduced platelet adhesion to collagen surface. In this 
experimental setup, thrombin is absent (due to quenching by PPACK at two different stages as 
well apixaban-prevention of thrombin production), which indicates that the reduction in platelet 
deposition is due to interaction between fibrin and GPVI, rather than an interaction between 
thrombin and GPVI. This result also lends strength to the argument that the attenuation effects 
seen in the previous calcium experiments is due to interaction between fibrin and GPVI rather 
than an interaction between fibrin and the collagen analog, convulxin. At 120s, low levels of 
fibrin resulted in more platelet deposition (+GPRP), while high levels of fibrin resulted in less 
platelet deposition on the collagen surface (Figure 2-6D).  GPRP had the same effect on platelet 
and fibrin deposition after 240s (Figure 2-6E).  
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Figure 2-6 Presence of fibrin reduces platelet adhesion on collagen (A) Experimental design. Fluorescent fibrinogen 
is exposed to 2.5 nM thrombin with either 5 mM GPRP (inhibit fibrin formation) or HBS (control). After 300 s, the 
thrombin is quenched with 100 μM PPACK to stop the fibrin polymerization reaction. This reacted fibrinogen/fibrin 
solution is diluted by a factor of 10 in PPACK/apixaban-inhibited whole blood with either 5 mM GPRP or HBS and 
then perfused through the 8-channel microfluidic device at 200 s-1 over a collagen surface. (B) GPRP increases platelet 
deposition on the collagen surface after 60 s. (C) Fibrin deposition is significantly decreased when with 5 mM GPRP 
from the HBS control. (D) At 120 s, low levels of fibrin resulted in more platelet deposition (+GPRP), while high 
levels of fibrin resulted in less platelet adhesion. (E) The same effects on platelet and fibrin deposition were observed 
after 240 s.  
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3.5 Discussion 
 
The fact that the addition of thrombin to PRP, but not ADP or the thromboxane mimetic, 
U46619, results in attenuation of convulxin-induced calcium mobilization when convulxin is 
added to PRP 480 seconds later indicates that the underlying mechanism for the downregulation 
of GPVI-induced calcium signaling is related to the unique function of thrombin in this assay. 
One of the functions of thrombin that is distinct from ADP and thromboxane in this assay is its 
ability to polymerize fibrinogen monomers into fibrin. The production of fibrin could play a role 
in the observed downregulation of GPVI-induced calcium signaling. Thrombin, with the help of 
metalloproteinases, has also been shown to induce low levels of GPVI-shedding [76, 77], albeit 
not to the extent that FXa and collagen or convulxin induces GPVI shedding. Another theory 
could be that thrombin induces SphK1 expression which increases formation of sphingosine 1-
phosphate (Sph-1-P) in platelets through PAR-1 signaling [78], and Sph-1-P has been shown to 
moderately but specifically abolish convulxin-induced intracellular calcium mobilization [78], 
although this is not quite likely given that the effect seen in Figure 2-1 was strong, not moderate.  
The results in Figure 2-2 indicate that the extent of the attenuation effect increases with 
thrombin dose as well as incubation time (time between initial thrombin dispense and subsequent 
convulxin dispense). The time scale in Figure 2-2C indicates that a maximum GPVI-signal 
attenuation effect was achieved at around 250 to 500 seconds (under 10 minutes), whereas 
thrombin-induced GPVI-shedding reached its maximum effect quite a bit later, around 30 to 40 
minutes [76]. In several experiments measuring thrombin-induced fibrin polymerization, fibrin 
levels were measured for a maximum of 15 minutes [79, 80], as the maximum value was usually 
reached before then. This time scale is more compatible with the timescale of the attenuation 
effect of convulxin-induced GPVI calcium signaling seen in Figure 2-2C.  This indicates that 
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polymerized fibrin binding to GPVI may better explain the observed GPVI-induced calcium 
response attenuation effect rather than thrombin (or fibrin) -induced GPVI shedding. 
Unlike thrombin, PAR-1 and PAR-4 receptor agonists cannot catalyze the polymerization 
of fibrinogen monomers into fibrin. The inability of PAR-1 and PAR-4 receptor agonists to 
reproduce the attenuation effect of convulxin-induced calcium response as created by thrombin 
(Figure 2-3) supports the hypothesis that fibrin plays an essential role in the subsequent 
convulxin-induced calcium attenuation effect. Thrombin activates PAR-1 with approximately 30 
times greater sensitivity than PAR-4, and PAR-1 activation induces a rapid increase in 
intracellular calcium that quickly returns to baseline, whereas the PAR-4 signaling provides a 
slower but more prolonged calcium increase [81]. Vorapaxar, a PAR-1 specific inhibitor, was 
able to completely abolish 10 nM thrombin-induced calcium signal (Figure 2-3B). This may  be 
because at 10 nM, which is a low to medium concentration of thrombin (5 x EC50), the thrombin-
induced calcium signaling might be dominated by signaling through PAR-1 rather than PAR-4, 
which is likely since thrombin activates PAR-1 with about 30 times greater sensitivity than PAR-
4  [81].  It has also been shown that PAR-4 receptor agonist (but not PAR-1) induced full platelet 
spreading on a fibrinogen matrix [82], which can be attributed to sustained calcium mobilization 
required for platelet spreading. The platelet spreading is thought to be mediated by activated 
integrin αIIbβ3, but the relatively new finding that fibrin binds to GPVI [16], may suggest another 
mechanism (through GPVI) by which platelets also spread on the fibrinogen matrix. This, along 
with the results in Figure 2-3C, may indicate that the interaction between platelet and fibrin that 
causes attenuation in GPVI-induced calcium signaling is largely dictated by PAR-4 rather than 
PAR-1.   
In Figure 2-4, GPRP (which inhibits the polymerization of fibrinogen into fibrin) 
abolishes the thrombin-induced attenuation effect on subsequent convulxin calcium response. 
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This strongly suggests that fibrin, not thrombin, is responsible for the attenuation effect. 
Furthermore, as seen in Figure 2-4C, GPRP also abolishes the upward calcium trend following 
thrombin peak (after thrombin addition to PRP), suggesting that the mechanism by which this 
phenomenon happens involves increasing calcium mobilization. This leaves four possible 
explanations: polymerized fibrin binding to GPVI, fibrin binding to convulxin/collagen, fibrin 
binding to another platelet integrin that mediates convulxin/collagen activation of platelets (such 
as integrin α2β1) or fibrin inducing GPVI-shedding. 
It has been discovered recently that platelet GPVI binds to polymerized fibrin (rather than 
fibrinogen monomers) [16, 18], which activates platelets (as shown by increased PS exposure) 
and promotes thrombin generation as well as thrombus growth [17]. In the platelet calcium assays 
done in this study, apixaban, a direct factor Xa inhibitor is used, which prevents endogenous 
thrombin generation. These results may shed light on the effect and nature of the fibrin-GPVI 
binding independent of thrombin generation.  
Regarding the possibility that fibrin induces GPVI-shedding, Factor Xa, collagen and 
convulxin, and to a much lesser extent, thrombin, have been shown to cause GPVI shedding [76, 
77]. To our knowledge, fibrin has not been studied as a potential cause of GPVI shedding. It 
could be that during the duration of thrombin-induced calcium mobilization, thrombin 
polymerizes fibrinogen into fibrin, which binds to and activates GPVI [16, 18], causing fibrin to 
cleave GPVI during the process, such that by the time convulxin is added, not enough GPVI is 
left on platelet membrane to be activated so as to lead to a GPVI-induced calcium influx. This 
may also explain the upward trend of thrombin-induced calcium mobilization in Figure 2-4A and 
Figure 2-4C; after an initial decrease after peak thrombin response, newly polymerized fibrin 
may activate platelets via binding to GPVI and induce calcium mobilization while cleaving 
GPVI, such that when convulxin is added a 480 seconds, very little GPVI is left intact to be 
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activated. In the condition involving GPRP (Figure 2-4C), thrombin-induced calcium 
mobilization is transient and returns to baseline because fibrin is not formed and therefore not 
continuously activating GPVI.  Similarly, when PAR-1 and PAR-4 receptor agonists were used to 
induce calcium mobilization, even though the peak calcium response was slightly higher than that 
of the thrombin-induced calcium response, calcium response was transient and returned to 
baseline because PAR-1 and PAR-4 cannot induce fibrin polymerization. The upward trend of 
thrombin-induced calcium mobilization may be also by aided by PAR-4 which has been shown to 
provide later but more sustained calcium mobilization than PAR-1 [83, 84].  GPVI shedding is 
regulated primarily by a-disintegrin-and-metalloproteinase 10 (ADAM10) [85]. Some other 
sources have also found that other members of the a-disintegrin-and-metalloproteinase family 
(such as ADAM17) also facilitate GPVI shedding [86]. These metalloproteinases (MMPs) are 
present in platelet rich plasma but is not present in washed platelets. In this washed platelet 
environment, we still see an attenuation of GPVI-induced calcium mobilization following 
thrombin addition in the control environment where fibrinogen is able to polymerize into 
fibrinogen, but not in the GPRP fibrin-inhibited environment. This makes it less likely that the 
attenuation effect seen here is due to polymerized fibrin cleavage of GPVI into sGPVI. 
Furthermore, as mentioned previously, the time scale in Figure 2-2C indicates that a maximum 
GPVI-signal attenuation effect was achieved at around 250 to 500 seconds (under 10 minutes), 
whereas thrombin-induced GPVI-shedding reached its maximum effect quite a bit later, around 
30 to 40 minutes [76]. Taken together, this weakens the argument that the attenuation effect is 
due to polymerized fibrin cleavage of GPVI into sGPVI. This can be further confirmed by 
repeating the experiments in Figure 2-4 in the presence of a broad spectrum metalloproteinase 
inhibitor such as GM6001 (since MMPs are essential for GPVI shedding). If the attenuation 
effect is still observable with successful GM6001 blocking of MMPs, then it is very unlikely that 
polymerized fibrin is causing GPVI shedding. 
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There is also the possibility that fibrin binds to convulxin, reducing its availability to bind 
to and activate platelet GPVI, resulting in the observed attenuation of convulxin-induced calcium 
mobilization. It is difficult to tell whether or not this is the case in the experiments done so far. To 
test this hypothesis, ligand binding assays can be done to examine the specific interaction 
between fibrin and convulxin or fibrin and collagen. 
  The procoagulant collagen surface in this microchannel causes platelet activation via 
GPVI and mediates adhesion through activated platelet integrin α2β1 [87-89]. Platelets tend to 
bind directly to the exposed collagen through two major receptors, integrin α2β1 and GPVI, only 
at high shear conditions are GPIb-V-IX receptor complex and its main ligand von Willebrand 
Factor additionally needed for firm platelet adhesion to the vessel wall [90]. Therefore, in this 
specific microfluidic assay, where shear rates are low (200s
-1
, corresponding to venous shear 
rates), the two possible mechanisms by which platelet deposition on collagen is reduced is via 
reduced platelet GPVI binding to collagen and/or reduced platelet integrin α2β1 binding to 
collagen. According to Niewswandt et al., GPVI but not α2β1 plays the central role in platelet-
collagen interactions under flow. GPVI facilitates platelet-collagen interactions by activating 
different adhesive receptors, including α2β1integrin; however, unlike GPVI, α2β1 integrin was 
found to strengthen adhesion without being essential to adhesion [91]. Therefore it is more likely 
that the reduction in platelet deposition on collagen observed here is due to reduction in GPVI 
binding to collagen rather than reduced α2β1 binding to collagen. Furthermore, it has been 
demonstrated that anti-GPVI antibody, but not anti-α2β1 antibody, inhibits convulxin-induced 
[Ca
2+
]i increase [92]. This also indicates that in convulxin-induced [Ca
2+
]i assays prior, attenuation 
effects seen were due to disrupted GPVI rather than α2β1 signaling. This leads to the most likely 
explanation of this observation: polymerized fibrin binds to GPVI. 
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In similar microfluidic assays, platelets tend to adhere to localized collagen surface 
within the first minute. Between approximately 1 minute and about 105 seconds, platelet 
coverage on the collagen surface grows in two dimensions. After 105 seconds, thrombus tends to 
grow in height (the third dimension) due to secondary platelet-platelet aggregation, mediated by 
soluble agonists such as ADP (around 105 seconds) and thromboxane (around 150 seconds) [93]. 
Therefore, in this experimental setup, to examine platelet GPVI interaction with collagen, the 
focus needs to be on the time window before 105 seconds. As seen in Figure 2-6B, around 60-
105 seconds, the GPRP platelet fluorescence intensity (FI) continuously increases over the 
control, indicating that platelet GPVI binding to collagen is reduced in the presence of fibrin. Pre-
60 seconds, there tends not to be a big difference, probably because fibrin is just being introduced 
into the system and the fibrin levels for the GPRP and control condition have not diverged 
enough yet (Figure 2-6C). To more closely examine this effect, the time resolution could be 
increased in the primary deposition phase (< 105 seconds). In the secondary platelet aggregation 
phase > 105 seconds, the platelet FI for the GPRP conditions continues to increase and diverge 
over the control condition, but appears to converge very slightly after 180 seconds. This could 
mean that polymerized fibrin disrupting the GPVI binding to collagen also has an initial effect on 
secondary aggregation that is corrected eventually, but this would require a repeat of the same 
experiment with higher time resolution to verify. There has been recent evidence that GPVI plays 
a critical role in thrombus growth and stability [16, 18] in addition to initiation; the fact that 
secondary aggregation as indicated by platelet FI > 105s continues to be reduced in the presence 
of fibrin suggests that fibrin binding to important sites on GPVI may be weakening its ability to 
grow and stabilize the thrombus > 105s.  
In Figure 2-6D, at both 120 and 240 seconds, fibrin, even in the control condition, does 
not show up in the spaces between the platelets (which is indicative of fibrin formed under flow), 
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which means that PPACK and apixaban have effectively prevented endogenous thrombin 
production as well as fibrin polymerization under flow. Further, the areas of fibrin fluorescence 
seem to overlay quite well onto areas of platelet fluorescence, indicating that platelets are where 
the fibrin is, which adds strength to the argument that platelets are binding to fibrin, possibly via 
GPVI. In previous work by Colace et al., whole blood (CTI-treated to inhibit coagulation by 
contact pathway) was perfused over tissue-factor treated collagen surface under pressure relief 
mode (which is a more physiologically relevant then the constant flow mode in Figure 2-6, 
because flow is diverted from thrombotic occluding channels to open channels which allows 
thrombus to grow to full occlusion) at a venous inlet flow (200s
-1
) [94]. The resulting average 
platelet mass formed in the presence of GPRP showed 20% more platelets than that formed 
without GPRP, suggesting a modest role for fibrin in slowing platelet deposition and clot growth, 
which supports our observation [94]. The effect of GPRP in our experimental setup, however, 
indicates a stronger role (platelet deposition seemed to decrease by slightly more than 50% in 
Figure 2-6B). 
In conclusion, the most likely explanation for reduced platelet deposition on collagen, 
reduced secondary aggregation, as well as attenuated calcium response to convulxin in the 
presence of polymerized fibrin is that polymerized fibrin binds platelet GPVI and therefore 
reduces GPVI-mediated platelet activation. However, the mechanism by which fibrin reduces 
GPVI-mediated platelet activation is not so clear. Fibrin could act as an antagonist or agonist (or 
both) when it binds to platelet GPVI. One way fibrin could act as an antagonist is by blocking or 
competing for GPVI-collagen and GPVI-convulxin binding sites when it binds to GPVI. 
However, recent findings show that fibrin binds to GPVI and promotes thrombin generation and 
thrombus growth [16, 18], effectively acting as a platelet agonist. This is not necessarily in 
contradiction to our findings; our experiments have examined this interaction in experimental 
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conditions where endogenous thrombin production is not possible due to use of Apixaban as the 
anticoagulant. Furthermore, in all calcium assays, thrombin-induced calcium signaling trends 
upward after the peak, but when GPRP is present to block fibrin polymerization, thrombin-
induced calcium signaling returns to baseline after the peak Figure 2-4C. This points to the 
possibility that fibrin produced by thrombin addition continuously activates platelets such that 
when convulxin is added 480 seconds later, platelets are already desensitized, resulting in the 
observed attenuated calcium signal. The mechanism for platelet desensitization still unknown but 
is important to further study. Patients with trauma-induced coagulopathy tend to have elevated 
markers of platelet activation but reduced responsivity to platelet agonists [15]. Trauma-induced 
coagulopathy is also marked by an increase in thrombin and fibrin generation [95]. The central 
observation in this work is a recapitulation of these trauma conditions in vitro: addition of 
thrombin initially activates platelets and initiates fibrin formation, resulting in platelet 
desensitization (manifested as an attenuated calcium response) to a strong platelet agonist, 
convulxin, when it was added 480 seconds later. Therefore, further investigating the underlying 
mechanism behind this central observation could be useful in understanding the mechanism 
behind platelet desensitization during trauma-induced coagulopathy.   
 
3.0 Future Work 
4.1 Further Investigation of Fibrin-GPVI Interaction  
The nature and effect of fibrin-GPVI interaction on platelet function, as highlighted in 
Chapter 3, requires further investigation.  
First, platelet GPVI also facilitates platelet aggregation indirectly by activating platelets 
and exposing phosphatidylserine (PS). An experiment could be conducted to study collagen-
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induced platelet aggregation in the presence of fibrin and without, in order to shed light on the 
effect of fibrin-GPVI interaction on platelet aggregation behavior, which is a platelet function not 
previously studied in Chapter 3. The experiment would entail drawing blood into 10% v/v sodium 
citrate and 250nM apixaban (to prevent endogenous production of thrombin).  Sodium citrate is 
required to prevent instant platelet aggregation upon agitation (from stir bars in cuvette), and does 
not affect the ability of thrombin to form polymerized fibrin from fibrinogen. The whole blood 
sample would be spun into PRP for light transmission aggregometry (LTA) to be performed. 
Vorapaxar , a PAR-1 inhibitor,  would be added to prevent full aggregation upon first dispense of 
thrombin but still allow thrombin to polymerize fibrinogen into fibrin. At the start of 
aggregometry reading, low dose thrombin (2 nM) would be added to PRP with or without GPRP 
(5mM) to inhibit fibrin polymerization. At 10 minutes after the first dispense, collagen would be 
added to induce platelet aggregation, the rate and final aggregation % would be read and 
compared between the conditions with and without GPRP to determine whether or not the fibrin-
GPVI interaction reduces platelet aggregation.  
As mentioned briefly in Chapter 3, it is unlikely that polymerized fibrin downregulates 
GPVI by inducing GPVI-shedding, as the attenuation effect is observable in washed platelets 
where the metalloproteinases (MMPs) needed for GPVI-shedding is theoretically absent. This 
statement can be verified by repeating the PRP calcium assay with GM6001, a broad spectrum 
inhibitor of metalloproteinases. It is expected that the results would be similar compared to that 
highlighted in Chapter 3 even in the presence of GM6001.  
Finally, the microfluidic assays performed in Chapter 3 may be improved with higher 
time scale resolution (higher than once per minute), especially since the important primary 
deposition phase occurs < 105. This allows us to better determine the timescale of the effect of 
fibrin-GPVI interaction on platelet deposition on collagen. 
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4.2 Extending human platelet calcium calculator to include individuals with 
familial hypercholesterolemia 
 The neural network-based calcium calculator (NN) built in Chapter 2 can be extended to 
include patient populations. This study would involve individuals with familial 
hypercholesterolemia (FH) and individuals without known coronary heart diseases who visit the 
doctor’s office to get a computed tomography coronary angiography (CTCA) scan. Pairwise 
agonist scanning (PAS) as described in Chapter 2 can be done on study participants and a NN 
trained exclusively on FH patients can be built. This FH-NN output can be compared to the 
healthy NN output [75] to shed light on the effect of FH on calcium signaling phenotypes. 
Furthermore, this NN can be combined with microfluidic experiments to build and validate a 
multiscale model to simulate thrombus growth and vessel occlusion triggered by collagen/tissue 
factor. This model may also be compared to the multiscale model built on healthy donors [53] to 
study how FH affects normal thrombus growth. Furthermore, with enough FH/healthy donors and 
PAS experiments, a classification model can potentially be built to identify and diagnose patients 
with FH based on their calcium signaling phenotype (for example using pairwise synergy scores).  
4.3 Combining platelet calcium calculator to build an NN-ODE model 
The neural network-based calcium calculator (NN) built in Chapter 2 can be coupled to 
an ODE model to predict important platelet activation phenomena in real time. Specifically, the 
NN built in Chapter 2 (which describes platelet receptor mediated calcium mobilization) can be 
coupled to a coarse-grained ODE model that further describes the effects of platelet activation 
events downstream of calcium mobilization such as: granule release, thromboxane and thrombin 
production, inside-out signaling and cell contraction. The production of secondary soluble 
mediators due to these events (such as ADP, thromboxane and thrombin) can be fed back into the 
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NN as inputs (in the form of agonist concentrations), resulting in a more comprehensive and 
accurate model of platelet activation and autocrinic signaling. It is important to note that the NN 
does not account for endogenous thrombin production and therefore does not capture the effects 
of autocrinic signaling [75]. Since the NN training incorporates feedback at 8 previous time 
points, history is important in the training of the NN. To enable the NN to more accurately give 
dynamic predictions in this ODE-NN coupling, the NN should additionally be trained on PAS 
experiments where agonists are added sequentially to improve the predictive power of the NN 
and avoid stability issues.  
The ODE model can be built to describe five important platelet activation events 
downstream of calcium mobilization, as shown in Figure 3-1. First, inputs (agonist 
concentrations) are to be specified. The NN can then predict intracellular calcium levels based on 
the inputs. All five events described in the ODE model are a triggered, at least in part, by 
intracellular calcium. Three of these events lead to production of soluble secondary mediators 
(ADP, thromboxane and thrombin). The ODE model will calculate the concentration of these 
secondary mediators based on intracellular calcium levels. The agonists concentrations will be 
fed back into the NN and the NN would predict the resulting intracellular calcium levels. This 
cycle continues until steady state is reached.  The signaling pathways triggered by elevated 
intracellular calcium levels in platelets are still largely unknown
 
[64].  Many of the kinetic 
parameters in the reactions that are involved in the known pathways events are unavailable/ 
difficult to determine experimentally [64]. Therefore a coarse-grained ODE approach can be 
used. Specifically, steady state experimental data that gives the concentrations of intermediates as 
a function of intracellular calcium levels can be found in literature, or if the literature is not 
available, it may be done experimentally (Table 1-1). With this coarse-grained ODE approach it 
is estimated that about 30 ODEs would be required to describe these five events.  
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Figure 3-1 ODE-NN model of platelet 
  
 Event Intermediates Studied/Coarse Grained Source 
1 ADP release Ca
2+
  Dense-granule release (coarse grained) 
Lenoci et al. (2011) [96] 
Jonnalagadda et al. (2012) 
[97] 
2 
Thromboxane 
release 
Ca
2+
  COX-1 activation  (Experiment) 
COX-1 activation  TxA2 production  (Experiment) 
3 
Thrombin 
release 
Ca
2+
  PS exposure (Experiment) 
PS exposure  Thrombin production  Chatterjee et al. (2010) [98] 
4 Aggregation  
Ca
2+
  α2bβ3activation (PAC-1)  Lenoci et al. (2011)
 
[96] 
α2bβ3activation   aggregation (KMC) 
Tandon et al. (1997) [99] 
Laurenzi (1997) [100] 
5 Contraction 
Ca
2+myosin activation (Experiment) 
myosin activation  contraction   
 
Table 3-1 Platelet activation events described in ODE model 
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Some of the coarse-graining experiments that can be done to measure those platelet 
activation events as a function of calcium, so as to obtain an effective rate, Keff, [96] include: for 
PS exposure as a function of [Ca
2+
]i , using Annexin V to measure PS exposure over time [101], 
concurrently measure [Ca
2+
]i using the same PRP sample and obtain a [PS-positive] vs. [Ca
2+
]i 
dataset. For TxA2 production as a function of [Ca
2+
]i, measure TxB2 (TxA2 converts to TxB2 
rapidly) using ELISA [102], concurrently measure [Ca
2+
]i using the same PRP sample, obtain a 
[TxA2] vs. [Ca
2+
]i dataset. Similarly, for phosphorylated myosin as a function of [Ca
2+
]i, measure 
myosin-P using [32P] – phosphorylated MLC12, concurrently measure [Ca2+]i using the same 
PRP sample, and obtain a [myosin-P] vs. [Ca
2+
]i dataset. 
Once the model ODE-NN model is built, experiments can be conducted to measure 
model performance. Inputs can be specified as agonist concentrations at t = 0, and a reliably 
measurable output would be thrombin concentration at t = tend.  Simulation can be run for ~10 
minutes (typical time for aggregation to plateau). Thrombin generation in response to agonists 
can then be measured in experiments using a thrombin-specific substrate, such as Boc-VPR-
MCA, in the well plate. The experimental thrombin generation result can then be compared to the 
simulation result in order to calculate accuracy and evaluate ODE-NN model performance.      
4.4 Higher order PAS  
The NN model that was trained on PAS (pairwise agonist scanning) in Chapter 2 can be 
improved by training the model on high-dimensional agonist scanning. The high-dimensional 
agonist scanning would include the effects of more than six agonists and improve accuracy of 
calcium level predictions.  
The complete experimental space for six agonists at null, low, medium and high 
concentrations (such as in PAS) is 4
6
 = 4096 conditions. There are approximately 20 more 
agonists not studied by PAS in Chapter 2 that are important in calcium signaling and platelet 
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activation as well (Table 3-2). The full experimental space grows exponentially with increasing 
number of agonists, the full experimental space for 20 agonists is 4
20 
, or approximately 1 trillion 
combinations.  Furthermore, we are limited to approximately conditions per experiment, mostly 
due to the lifetime of PRP in 250nM apixaban. Therefore it is important to establish a systematic, 
“smart”, efficient sampling method to sufficiently inform the neural network such that is able to 
make reasonably accurate predictions about the complete experimental space.  
In Pairwise Agonist Scanning (PAS), platelets are activated with all single and pairwise 
combinations of six agonists at three different conditions (154 conditions total including a null 
condition). Each agonist activates different receptors on the platelet. Significant crosstalk occurs 
between these different receptor-mediated signaling, but they all converge on calcium 
mobilization. As explained previously in Chapter 2, NN trained only on the resultant calcium 
time traces of single and pairwise interactions in the full agonist dose range was able to predict 
trinary, higher order (4-6 agonists) and sequential interactions with reasonably high accuracy 
[75]. The trinary, higher order and sequential experiments were done separately and was not part 
of the training set. The fact that just single and binary conditions were enough to inform the NN 
about conditions involving 3-6 agonists points to the possibility that there are redundancies in the 
information provided by some of the combinations. In other words, certain agonist combinations 
may not be so informative or important in describing the full experimental space. The search 
method may be guided by the synergy score metric previously developed by Chatterjee et al. 
(2010) [20].  Synergy scores are a measure of the direction and extent of cross-talk between 
agonist combinations [20]. Synergy scores (Sij) range from -1 to 1. A positive Sij value indicates 
synergistic behavior between agonists i and j whereas a negative Sij value points to antagonistic 
behavior; a Sij value of 0 represents a purely additive response. Combinations with high synergy 
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scores contain information about cross talk between signaling pathways beyond the additive 
response of the single agonists that the combination comprises. 
In other words, the complete experimental space for six agonists at null, low, medium 
and high concentrations is 4
6
 = 4096 conditions. A method can be developed to probe the 
important directions (i.e. perform “smart” sparse sampling of combinations) such that the NN is 
sufficiently informed and able to predict calcium time traces of the full combinatorial space 
(specifically higher-order interactions). This is a fractional factorial design problem: the full 
combinatorial experimental space is strategically sampled by utilizing the sparsity-of-effects 
principle so as to reduce screening effort. The sparsity-of-effects principle states that a system is 
usually dominated by main effects and low-order interactions. That method can then be utilized to 
determine specific combinations of agonist (not limited to the six mentioned in Chapter 2) that 
would be most informative, so that experiments can be done to obtain corresponding calcium 
time traces and a neural network can be trained on just those calcium traces but still be able to 
predict calcium response to > 6 agonists.   
One possible method to develop the “smart” sparse sampling method is to use synergy 
scores (Sij) to point toward combinations that are most informative.  For a given combination, 
high absolute Sij values of synergy scores indicate that significant cross-talk takes place between 
the signaling pathways mediated by agonists involved in that given combination. In other words, 
that combination is information-dense. On the other hand, combinations for which Sij values are 
close to zero demonstrate only the additive response of the single agonists that make up that 
combination – this information is already captured by the single agonist conditions. 
Experimentally, we are limited to approximately 190 conditions per experiment. Full main effects 
for the complete 4
6
 (6 agonist) experimental space as well as the full n = 135 second order 
interactions (100% of 135 possible interactions) are already sampled. The Sij for each of the 135 
sampled combinations should then be examined, and combinations that satisfy a certain threshold, 
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e.g. |Sij| > 0.3 can be picked. Utilizing data from Chapter 2, there are about 20 (out of a total of 
160) combinations that satisfy this criteria for example. This process would then be repeated for 
each interaction order (third and higher). Next, n = 190 third order interactions would then be 
randomly sampled and the corresponding Sij calculated. If the same example threshold was set, 52 
(out of 160) combination satisfy this criteria. This is then repeated for each order interaction (4, 5 
and 6). The sample size n for each order interaction will also have to be scaled to each order 
interaction combination space (i.e. sample size for the six-agonist experimental space has to be 
larger than the three-agonist experimental space).  Other rules or methods for picking the samples 
may also be explored (e.g. Random Sampling-High Dimensional Model Representation, Markov 
Chain Monte Carlo, Non-linear PCA/ Diffusion maps, Locality-sensitive hashing).  
Next, prediction R values (representing accuracy of model) will have to be plotted against 
sampling effort (effectively number of combinations sampled). We would stop at a point (i.e. pick 
the number of combinations sampled) where prediction ability plateaus with increasing sampling 
effort. Then the full 20-agonist experimental space 4
20
 can be sampled with approximately 20 
experiments using one of the methods above to obtain a reasonable R value for prediction.  
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List of Important Platelet Agonists [103]
 
 
  Agonist Receptor Phase 
1 Collagen (Convulxin) GPVI 
Recruitment, Adhesion, Aggregation 2 
Fibrinogen, vWF, 
fibronectin, vitronectin, TSP-1 α2bβ3 
3 Fibronectin α5β1 
4 Laminin α6β1 
5 ADP P2Y1, P2Y12 
Amplification 
6 Thrombin PAR-1, PAR-4 
7 Thromboxane (U46619) TP 
8 
1-O-alkyl-2-acetyl-sn-
glycero- 
3-phosphocholine PAF receptors 
9 Lysophosphatidic acid Lysophosphatidic acid receptor 
10 Vasopressin V1a vasopressin receptor 
11 Adenosine A2a adenosine receptor 
12 Epinephrine b2 adrenergic receptor 
13 
Serotonin (5-
hydroxytryptamin) Serotonin receptor 
14 Dopamine Dopamine receptor 
15 ATP P2X1 
16 TPO c-mpl 
17 Leptin Leptin receptor 
18 Insulin Insulin receptor 
19 PDGF PDGF receptor 
20 Ephrine Ephr 
Stabilization 
21 Gas-6 Axl/Tyro3/Mer 
22 PSGL-1,GP1b,TF P-selectin 
23 
TSP1, oxLDL, VLDL,  
oxPHL, collagen type V CD36 
24 PACAP VPAC1 
Negative Regulation 
25 PECAM-1 PECAM-1 
26 PGI2 IP 
27 PGE2 EP1-4 
28 PGD2 receptor PGD2 
Table 3-2 List of Important Platelet Agonist compiled from Kauskot et al. (2012) 
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4.5 Building a classification based on platelet calcium mobilization 
phenotypes as measured by pairwise agonist scanning 
The project described in section 4.2 (PAS experiments of FH patients) may be combined 
with large quantities of available PAS experimental data of healthy donors in past years as well as 
in the future to build a data-driven classification model that distinguishes patients from healthy 
donors based on PAS calcium phenotypes (for example synergy scores). If proven to be accurate, 
such a model may be able to aid in clinical diagnosis in the future. Once trained on PAS data of 
both healthy donors and patients, the model would be able to classify new donors as ‘healthy’ or 
‘patient’ based on their PAS calcium phenotype. A plausible approach to building a classification 
model that exploits the wealth of platelet function information in the PAS experiments is 
described below.  
In this example, I built a classification model that distinguishes male donors from female 
donors using a PAS dataset generated by a previous Diamond Lab member, Manash Chatterjee.  
The PAS experiments were performed by Manash Chatterjee as previously described [20]. I 
decided to use the 135-parameter synergy score of each PAS experiment as the calcium 
phenotype to build my classification model on. As mentioned previous in Chapter 2, synergy 
scores (Sij) are a measure of the direction and extent of cross-talk between agonist combinations. 
The synergy score is defined as the difference between the observed and the predicted additive 
calcium level response, normalized by scaling to the maximum synergy score observed in the 
entire dataset. Synergy scores range from -1 to 1. Negative values for a particular pair of agonist 
conditions indicate antagonistic behavior, whereas positive values indicate synergistic behavior. 
A synergy score of 0 indicates a perfectly additive response. In previous work, synergy scores of 
replicate PAS experiments done on the same donor on different days self-clustered [20], 
demonstrating that synergy scores is a quantifiable platelet phenotype that describe an 
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individual’s unique platelet function. In addition to predicting the sex of the donor based on the 
donor’s PAS data, the classification model may also be used to point toward the key 
physiological differences that are the most informative, in this case, isolate the specific synergy 
scores (specific combinations of agonist) that are most predictive of donor sex. 
4.5.1 Gender clustering patterns 
To first demonstrate that the gender of donors had an effect on PAS synergy scores, 
hierarchical clustering was done on the 135-element synergy score vectors of 40 PAS 
experiments.  The Euclidean distance between synergy score vectors between all pairs of synergy 
score vectors were calculated and was used as the measure of similarity between each vector. 
Experiments from the same donor self-clustered at the lowest level On a higher level, male 
donors (black text) tended to cluster together on the left and female donors (red text) tended to 
cluster together on the right (Figure 3-2). This indicates that both the identity and gender of 
individual donors can be distinguished based on their PAS synergy scores, and alludes to a 
potential phenotypical difference between male and female platelet reactivity.  
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Figure 3-2 Clustering of synergy scores based on donor gender 
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4.5.2 Sources of variability in synergy scores 
Inter-donor variability was calculated by first taking the average synergy scores of the 
replicate experiments of each donor, then calculating the standard deviation of average synergy 
scores among donors. The biggest differences in sources of variability between male and female 
donors come from medium and low CVX interactions (Figure 3-3). Among female donors 
(Figure 3-3 middle panel), as opposed to among male donors (Figure 3-3 top panel), those 
interactions did not contribute very much to variability. PAR-1 receptor agonist, AYPGKF 
pathways also contributed to variability among donors, but its contribution is significant both in 
men and women (Figure 3-3bottom panel). This indicates that GPVI signaling and crosstalk 
accounted most strongly for the functional differences between the male and female platelets. 
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Figure 3-3 Sources of variability in synergy scores 
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4.5.3 SVM model building and performance 
The classification model was built using support vector machines (SVM). SVM was 
implemented using libSVM software written for MATLAB. The dataset was first organized into a 
40 x 135 matrix of synergy scores. Each row comprised of a synergy score vector of a particular 
PAS experiment. There were 20 total donors in this dataset, 10 of which were female and 10 
others were male. Each donor had a set of two replicate experiments, giving a total of n = 40 PAS 
synergy score vectors. There were m = 135 pairwise conditions of the 6-agonist PAS experiment. 
Labels were then prepared as a binary column vector with 0 representing the male donors and 1 
representing female donors. The synergy scores ranged from -1 to 1. To reduce computational 
time, the dataset was first preprocessed into integers that ranged from 1 to 64. All datasets were 
also kernelized using the intersection kernel before being trained on by the Support Vector 
Machine (SVM) algorithm. The new dataset was then normalized by dividing synergy scores by 
the maximum value of each condition. The dataset was then randomly divided in an 80/20 
proportion into training and testing sets, with the constraint that there were equal numbers of male 
and female donors in the training and testing sets. This constraint was put in place because of the 
relatively small size of the dataset (n = 40); making sure that the training set had equal numbers 
of male and female donors would enable the SVM method trained to be more accurate despite the 
small size of the dataset. Leave-one-out-cross-validation (LOOCV) was then performed on the 
training set (consisting of 32 examples) to determine the best C-parameter to use for the actual 
training and testing. The C-parameter in SVM represents the extent to which the SVM algorithm 
allows classification errors during training. In LOOCV, one example is randomly set aside as a 
test sample and the rest are trained with SVM using a chosen value. This is repeated 100 times to 
obtain an overall error rate. This procedure is repeated with different C-parameters (100, 200, 
500, 1000 and 10000), and the final C parameter chosen would be the one that produces the 
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lowest error rate. Then the SVM is trained on the original training set using the cross-validated C-
parameter value and finally tested to obtain the test error. This entire procedure we repeated 1000 
times to obtain an overall 1000-run test error.   
In this SVM implementation, the dataset was split randomly into training and testing sets 
in an 80/20 proportion, with the constraint that there were equal number of male and female 
donors in each of the training and testing set. The training set further underwent LOOCV and 
SVM training using the cross-validated C parameter. This procedure was repeated 1000 times, 
each time the dataset was split randomly. As a result the average error rate over 1000-runs was 
5.975%. The error matrix is a visualization of this experiment (Figure 3-4a); each row represents 
a test example, each column represents a single run of the procedure. Green represents instances 
that gender was correctly predicted, black represents instances where gender was incorrectly 
predicted  (Figure 3-4a). The top four vectors in the figure represent male donors whereas the 
bottom 4 test vectors represent female donors (recall that these may not be the same donors each 
run because of the random split of testing and training data) (Figure 3-4a). Though there are 
20
C4 
X 
20
C4  possible splits of the data (about 23 million), a 1000-run sampling is enough to get a 
representative error rate. The procedure was also repeated 10,000 times, and for that run the error 
rate was very similar: 5.7888%.  
 
4.5.6 Agonist elimination to elucidate platelet calcium signaling pathways most predictive of 
gender 
To determine which agonist interactions in the synergy scores were most important in 
determining the gender, synergy scores involving certain agonists were omitted from the training  
and the resulting overall 1000-run test error compared. In each of the 1000 runs, the data was first 
randomly divided into training and testing sets before each agonist was omitted. This was to 
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ensure that differences in random training/testing set divisions did not contribute to the 
differences obtained between 1000-run test error trained on the full dataset and that of the 
agonist-omitted dataset. If the 1000-run test error of a particular agonist-omitted dataset was 
higher than that trained on the full dataset, then that agonist is useful in predicting the gender of 
donors. Each agonist-omitted dataset were also compared to each other so as to rank the 
importance of each agonist in predicting gender of donors. This would provide insight as to which 
agonist pathways were most different between males and females.  
The average 1000-run prediction error is plotted for each agonist omission. (Figure 3-4 
top right panel) The highest average prediction error (12.325%) occurred when synergy 
conditions involving the convulxin agonist were omitted from the training set. (Figure 3-4 top 
right panel)This result agrees with the inter-donor variability of synergy scores (Figure 3-3). The 
most notable differences in sources of inter-donor variability of synergy scores between and male 
and female donors came from interactions of medium and high-dose convulxin. This difference 
could have contributed to the predictive power of the SVM algorithm when convulxin-related 
synergy scores were included in training set. Since convulxin is a GPVI receptor, this result also 
alludes to a possible underlying phenotypical difference in GPVI-activation pathways between 
male and female donors. Neeves et al. (2013) reported that women had higher platelet 
accumulation than men on fibrillar collagen in microfluidic flow assays [104].
 
However, women 
also had higher Von Willebrand Factor (vWF) levels than men, so these variables were not 
decoupled [104]. So far, there aren’t any conclusive differences between male and female platelet 
function. The error rate dropped below the original prediction error with no omission of 5.6625% 
when AYPGKF, the PAR-1 agonist peptide was omitted from the training dataset (2.838%) 
(Figure 3-4 top right panel). In other words, the algorithm did better (prediction error halved) 
when AYPGKF-related synergy conditions were removed from the training dataset. This could 
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mean that there are little differences in platelet activation pathways via PAR-1, and the relatively 
high contribution of AYPGKF to inter-donor variability of synergy scores added to the noise of 
the training dataset, and therefore caused SVM method trained to be less effective at predicting 
error. The agonist-omission error bar plots were created for male donors and female donors 
separately (Figure 3-4 right middle and right bottom panel).  There seemed to be differences in 
predictive powers of the algorithm for male donors versus female donors, which could be fixed 
with introducing a bias term in the SVM algorithm. 
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Figure 3-4 (a) SVM model performance (b) Impact of specific agonist elimination on SVM model performance 
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4.5.3 Implementation of SVM on reduced dimension (3D) dataset 
This exercise was done for the purpose of visualization and understanding of the SVM 
method used to build this classification model. The 135-dimension PAS synergy score dataset 
was projected onto its top three principal components using the principal component analysis 
(PCA) function in MATLAB. The top three principal components are the dimensions in which 
the largest variability of the data is captured. The 135-dimension synergy scores are then 
projected onto those three principal components to produce the 40 data points as visualized in 
Figure 3-5.  When SVM was implemented on the reduced dimension (3D) dataset, the resulting 
maximum margin hyperplane is a flat 3-D plane, with quite a few classification errors on each 
side (Figure 3-5).  When SVM was done on the full 135-D dataset, the test error over 100-runs 
was 5.75% (Figure 3-4), whereas that for the 3-D dataset was 32.12%. Even when SVM was 
trained on the PCA-reduced 30-D dataset, the 100-run error only decreased to 22.5%. This 
indicates that none of the synergy scores are extraordinarily uninformative in predicting gender of 
the donors. In other words, the synergy score vectors data is not noisy. When the training data is 
3-D, the SVM hyperplane is a 3-D plane. In this dataset, the training data is 135-D, though it is 
difficult to visualize the hyperplane that separates the two classes spans 135 dimensions. 
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Figure 3-5 Implementation of SVM on reduced dimension (3D) dataset 
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Appendix A: Dose Response Curves for Platelet Agonists 
 
Figure A-3-6 Dose response curves of each agonist. This set of dose response curves were obtained for a single donor 
done in quadruplicate, and is representative of the dose response curves for the total of six donors used to calculate the 
average EC50 values shown in the table inset. EC50 values were calculated by fitting a four-parameter hill function 
curve (dashed lines) to the area under curve of the baseline-normalized fluorescence intensity (F/F0) calcium time 
course. For the dose response of platelet antagonist iloprost, platelets were simultaneously stimulated with PAR-1 
agonist SFLLRN (40μM). For the dose response of platelet antagonist GSNO, platelets were simultaneously stimulated 
with 1μM ADP 
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Appendix B: Investigation of Autocrinic Signaling Effects in PAS 
 
Figure A-2 Investigation of autocrinic signaling effects. To determine whether or not significant secondary 
autocrinic amplification effects by ADP and thromboxane secretion were present in the PAS assays, apyrase (ADP 
hydrolyzing enzyme, 2 Units/ml) and indomethacin (COX-inhibitor,15μM) were used. GSNO, Iloprost, U46619, 
thrombin and convulxin at 0.1, 1, or 10 X EC50 were added to platelets in similar conditions as in the PAS experiments 
(12% PRP, 250nM Apixaban). In the case of the inhibitors GSNO and Iloprost, platelets were co-stimulated with 
60mM SFLLRN, a PAR-1 activator. Only one of the 60 conditions tested with added inhibitors produced a detectable 
reduction in calcium signal (one-tailed T-test P < 0.05).   
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Appendix C: Neural Network Prediction of Trinary Combinations 
 
Figure A-3 Neural network prediction of the trinary combination experiment. Experimental and NN-predicted 
calcium traces are plotted for all 160 trinary conditions (all single and trinary combinations of agonists at two 
concentrations: 0.1x EC50 and 1x EC50). Rescaled to 0.5 for easy visualization. 
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Figure A-3 Neural network prediction of the trinary combination experiment. Experimental and NN-predicted 
calcium traces are plotted for all 160 trinary conditions (all single and trinary combinations of agonists at two 
concentrations: 0.1x EC50 and 1x EC50). Rescaled to 0.5 for easy visualization. 
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